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ABSTRACT 
 
Cutaneous squamous cell carcinoma (SCC) is a type of non-melanoma skin cancer.  SCC is the 
second most common skin tumor with a lifetime risk of 7-11 percent.  It is a neoplasm of 
epidermal keratinocytes characterized by loss of cellular structure and architecture.  The 
molecular pathways leading to the development of SCC remain poorly defined.  Loss of 
heterozygosity (LOH) in tumors is a frequent event contributing to tumorigenesis.  Homozygous 
loci have two identical alleles or DNA sequences, and a higher frequency of genomic 
homozygosity has been observed in normal DNA from cancer patients compared to controls.  
Thus, there may be an increased likelihood that stretches of consecutive homozygous markers, or 
runs of homozygosity (ROH), may occur at loci containing cancer susceptibility genes.  Based 
on these observations, our first hypothesis is that ROH are more frequent in normal DNA from 
individuals with SCC.  Secondly, we hypothesize that certain single nucleotide polymorphisms 
(SNPs) are associated with risk of SCC. To test these hypotheses, DNA from SCC patients and 
controls were genotyped at 123 SNPs mapping to Chromosomes 7 and 11 by Sequenom Mass 
ARRAY.  We observed similar frequencies of homozygosity in cancer and non-cancer patients 
and no significant ROH were identified.  One SNP on chromosome 7 and two SNPs on 
chromosome 11 had significant odds ratios (OR) for SCC risk in the homozygous state.  Three 
SNPs mapping to Hdac9 on chromosome 7 and five SNPs mapping to DRD2 and KIRREL3 on 
chromosome 11 show protective effects.  From these data, we conclude that some SNPs on 
chromosome 7 and 11 may increase the risk of developing SCC and others promote protection.  
We found Hdac9, DRD2, and KIRREL3 to be potential candidate genes that affect SCC 
susceptibility.  Additional studies are needed to confirm these results and identify skin cancer 
susceptibility and resistance genes. 
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CHAPTER 1 
INTRODUCTION 
1.1 Biology of the Skin 
Skin cancer is the most common human cancer and is typically classified as melanoma 
skin cancer or nonmelanoma skin cancer (NMSC).  Melanoma arises from the malignant growth 
of the melanocytes, skin cells that produce the pigment melanin, and NMSC originates in the 
external surface and epithelial layers of the skin.  One in five individuals will develop NMSC in 
their lifetime, and the chance of developing this disease is greater than that of any other type of 
tumor1.  Economically, skin cancer places a significant pressure on health care, resulting in 
treatment costs of over $500 million annually in the United States2.   
NMSC is further divided into basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC), both of which originate from malignantly transformed epidermal keratinocytes in the 
basal and squamous cell layers respectively3.  BCC is the most frequent skin tumor and makes up 
about 80% of diagnosed cases (www.cancer.org).  SCC is the second most frequent skin tumor with 
a lower lifetime risk (7-11%) in comparison to BCC (18-33%)4.  This study will focus on SCC. 
SCC tumorigenesis is often described as a multistep process affecting the squamous (flat, 
scale-like) cells that make up the most superficial layer of the epithelium5.  Actinic keratoses 
(AK), also known as solar keratoses (SK), are well-established sun-induced precancerous lesions 
that progress to SCC in situ, a continuation of keratinocyte dysmaturation and atypical cell 
structure and formation.  SCC in situ is characterized histologically by the abnormal 
development of keratinocytes throughout the full epidermis, representing a preinvasive stage of 
SCC6.  Keratoacanthomas (KA) are benign cutaneous squamous neoplasms that also arise from 
UV exposure and share similarities with SCC in growth rate and morphology.  It is currently 
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being debated as to whether or not KAs are part of the development of SCC.  SCC is described 
as a neoplasm of epidermal keratinocytes characterized by loss of cellular structure and 
architecture.   
The major environmental contribution to the development of human skin cancers is UV 
light through sun exposure.  Despite the benefits of UV, such as its role in vitamin D synthesis 
and stimulating the production of skin pigmentation, UV is a complete carcinogen that is capable 
of promotion, initiation, and progression of skin cancer.  It causes photodamage and other 
negative effects of the skin.  For instance, UV radiation can result in mutations such as DNA 
nucleotide dimers, the peroxidation of lipids, and protein crosslinking7.  There is an abundance 
of evidence that UV exposure is a contributor to skin cancer.  In animal models, UV radiation 
has been shown to be sufficient enough to produce skin cancer in mice8.  Consistent with this, 
the development of skin cancer occurs at a higher frequency at sites that are exposed to UV, such 
as the head and neck.  Consequently, the rates of developing skin cancer are low in rarely UV-
exposed areas like the buttocks.  Chronic exposure to UV radiation also predisposes an 
individual to NMSC.  Additionally, individuals with the genetic disorder xeroderma 
pigmentosum (XP) are deficient in repairing UV-induced DNA damage and are therefore more 
likely to develop skin cancer in sun exposed areas without protective measures.  Lastly, 
individuals with sensitive skin that burns easily, such as those with fair skin, are more 
susceptible to the development of skin cancer9. 
 
1.2 Genetics of Skin Cancer 
As of today, the exact molecular pathways that convert normal epidermal cells to SCC 
remain poorly defined.  However, there have been number of studies on the genetic changes that 
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occur in skin cancer tumorigenesis.  UV light has the potential to induce somatic (non-heritable) 
DNA mutations.  The most investigated of these aberrations is mutation-associated inactivation 
of the tumor suppressor gene p53.  p53 is important in DNA repair, as it regulates the cell cycle 
and triggers apoptosis (programmed cell death) of damaged cells to prevent their proliferation.  
Not only is p53 a hotspot for mutations, but differential expression of p53 response elements 
have been observed10.  For example, keratin 15 (KRT15) is a p53 response element that is 
downregulated in SCC, thus affecting the integrity of cellular architecture.  Abnormal 
keratinocyte differentiation in SCC is possibly caused by the disruption of gene activation and/or 
repression during the differentiation cycle.  Chronic UV radiation and p53 mutations, specifically 
C  T transitions, can result in the dysregulation of apoptosis and the abnormal proliferation of 
keratinocytes.  AK lesions, considered to be precursors to SCC, contain a high frequency of p53 
mutations that are also found to be present in SCCs11.  
Currently, there is little known about specific genetic risk factors and susceptibility to 
SCC.  However, a few studies have suggested genetic predispositions to the disease.  In a 
Swedish population-based study, a family-shared environmental effect of 17-18% was found12.  
This shared effect may be partially caused by familial habits of sun exposure.  SCC was found to 
have a genetic contribution of 8% and a childhood-shared environmental contribution of 7%.  
Previous studies of genetic contributors to this disease have found an increased relative risk of 
2.7 in individuals who have a family member with SCC compared to individuals with no family 
history of SCC.  Inherited traits within families, such as skin type and pigmentation, can also 
lead to the common sensitivity to UV radiation and an increased risk for skin cancer. 
One common feature in cancer cells is genomic instability, which is caused by either 
inherited mutations in genes important for genome integrity or mutations acquired in somatic 
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cells during tumor development13.  These genetic alterations can occur at the level of single 
nucleotides, small stretches of DNA, whole genes, or complete chromosomes and their 
structures.  Specific to SCC development, chromosomal aberrations such as gains, losses, and 
translocations have been identified14.  SCCs experience high chromosomal instability, and a 
number of these have been and are being studied today to find genes implicated in this disease.  
The investigation for these genetic changes in SCC and other cancers has led to the development 
of various genomic studies and findings.   
 
1.3 Genomic Studies 
1.3.1 Single Nucleotide Polymorphisms and Alleles  
 With the completion of the Human Genome Project, it is now possible to use genome-
wide association studies (GWAS) to identify susceptibility genes.  GWAS are used to detect 
genetic differences between genomes of individuals with and without disease.  These studies 
rapidly scan specific markers across a genome to find common genetic variations that are 
associated with a particular phenotype (disease).  Identifying these differences can help elucidate 
the possible genetic contributions to disease.  Genetic markers that are often used in GWAS are 
single nucleotide polymorphisms (SNP).  A SNP is a DNA variation at a single nucleotide 
position in the genome.  SNPs can potentially affect gene regulation or later protein production 
by altering mRNA and the protein reading code.  Changes in the genome can affect the 
predisposition one has towards a disease, and can alter the function of susceptibility genes and 
other genes that confer resistance. 
SNP mapping technologies like SNP genotyping arrays are used to detect polymorphisms 
and determine genotypes.  These technologies have made it possible to study chromosomal 
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aberrations in more detail.  By using mapping technologies, deviations from what is considered 
genetically normal can be measured.   
Genotypes reflect the genetic makeup of an individual and typically consist of two 
alleles, one inherited from each parent.  In normal cells, an individual has two copies of DNA, 
each called an allele, from every region in the genome with the exception of the X and Y 
chromosomes.  Sometimes these regions share the same version of a SNP (homozygous) and 
sometimes they have different versions (heterozygous). 
 
1.3.2 Allelic Imbalance and Loss of Heterozygosity 
SNP genotyping arrays have been used as a tool to identify candidate genes, which are 
genes believed to influence phenotype expression in a way that confers risk to a disease, such as 
cancer.  GWAS such as genotyping arrays are important tools for describing the genetic events 
that underlie the cause and progression of cancer.  One genome-wide allelic imbalance study 
found deletions within the tyrosine phosphatase receptor type D (PTPRD) on chromosome 9 in 
tumors.  PTPRD is associated with metastasis and is a possible candidate tumor suppressor gene 
for cutaneous SCC15. 
SNP genotyping arrays are also used to study allelic imbalance, a differential and altered 
expression in copy number between two alleles.  Alleles are alternate forms of a gene at a 
specific position on the chromosome, such as a nucleotide.  Allelic imbalance is the loss or gain 
in genetic material and is detected by measuring allele or nucleotide frequencies.  Normally, an 
individual has two copies of DNA.  However in tumors, changes can occur that result in losses or 
gains of DNA. 
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One type of allelic imbalance that has been studied in cancer tissues is loss of 
heterozygosity (LOH)16.  A loss of heterozygosity is the loss of one allele and its normal 
function.  LOH is a common form of mutation in cancer, where its presence suggests the loss of 
a functional tumor suppressor gene.  In cancer, the Knudson 2-hit Hypothesis is an explanation 
of LOH in tumors.  This concept encompasses both germline predispositions and somatic 
mutation events to inactivate tumor suppressors.  Therefore, it applies to heritable cancer 
syndromes.  The first hit is an inherited mutant allele in the germline.  Although one allele is 
mutated, the other is a normal, wild-type allele.  With the second hit, there is a somatic loss of 
the wild-type allele.  As a result, a single mutant allele is expressed, thereby altering the normal 
functions of the cell and beginning the process of tumorigenesis.  The second hit may be caused 
by a variety of complex somatic events.  
  Recent studies have shown that LOH is common at cancer susceptibility loci.  A 
heterozygous locus consisting of a wild-type (cancer resistant) allele and a mutant (cancer 
susceptible) allele loses its resistant allele, resulting in the expression of its susceptibility allele.  
Mechanisms by which LOH occurs include deletions, amplification and over-expression of the 
mutant/susceptibility allele, and mitotic recombination (Figure 1). 
 
1.3.3 Runs of Homozygosity 
A related and newly described concept to LOH is runs of homozygosity (ROH), which is 
currently being studied as a possible contributor to disease.  A ROH is a long continuous stretch 
of homozygous alleles or SNPs in the genome (Figure 2).  Researchers studying schizophrenia 
developed an analytic approached to examining SNPs called whole-genome homozygosity 
association (WGHA) 17.   WGHA leads to the identification of ROH that are associated with 
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disease.  By applying WGHA to a case-control dataset for the psychological disorder, Lencz et 
al. found a greater frequency of ROH in schizophrenia patients than in the normal population.  
Nine ROHs were identified as potentially significant ‘risk’ factors for this disease.  ROH have 
also been observed in other diseases including autism and Alzheimer’s disease18. 
Given that some regions of homozygosity stretch for a relatively long distance of DNA 
and the presence of numerous tumor suppressor genes in the genome, there is an increased 
likelihood that stretches of consecutive homozygous markers occur at loci containing cancer 
susceptibility genes.  Homozygous loci can arise by gene conversion during carcinogenesis, and 
have previously been associated with cancer.  It is possible that ROH contributes to an increased 
cancer risk and predisposition.  One study reported the identification of 114 loci with increased 
frequencies of heterozygosity in genomic (normal) DNA of breast and prostate cancers, and head 
and neck SCC in comparison to matched controls.  Regions of homozygosity have also been 
found in normal tissues of colorectal cancer patients19.  Therefore, homozygosity is an important 
genetic factor that influences cancer predisposition. 
 
1.4 Identification of SCC Susceptibility Loci 
Results from Dr. Amanda E. Toland’s research lab have provided some background on 
SCC susceptibility loci by utilizing the divergence of Mus spretus from M. musculus in mouse 
studies.  M. spretus is resistant and M. musculus is susceptible to chemically-induced skin 
cancer.  To identify loci for skin cancer susceptibility, backcrosses between the two species were 
created.  Skin tumor susceptibility 5 (Skts5), located on mouse chromosome 12, was identified as 
a susceptibility locus.   Sequencing of genes and coding elements that mapped to the peak 
linkage area for Skts5 for each of the different cross-strains was conducted to identify skin cancer 
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susceptibility candidate genes20.  The Skts5 region on mouse chromosome 12 maps to two 
regions on human chromosome 7 (Figure 3). 
Additional studies to map loci important for SCC were also conducted in the Toland lab.  
One study conducted genotyping of human SCC tumors and matched genomic DNA using 
microsatellite markers to detect loci showing preferential allelic imbalance (losses and gains) 
(Dworkin et al. submitted).  This study found multiple chromosomal regions showing 
preferential allelic imbalance and identified significant markers for these imbalances on 
chromosome 11 (Figure 4).  A number of SNPs on 11q23-11q24 were identified to show strong 
evidence for preferential allelic loss.  Specifically, 11q24 showed significant somatic preferential 
allelic imbalance, and this locus was identified as a new candidate tumor susceptibility locus for 
SCC (Dworkin, A.M. personal communication). 
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Figure 1: Loss of Heterozygosity (LOH).  In cancer, a heterozygous locus on sister chromatids 
has one resistance allele (red) and one susceptible allele (green).  LOH occurs when the 
heterozygous locus loses its functional resistance allele, resulting in only the susceptible allele 
being present.  LOH can occur by multiple mechanisms including deletion of the resistance 
allele, amplification of the susceptibility allele, or by mitotic recombination. 
 
 
 
Figure 2: Runs of Homozygosity (ROH). Homozygous genotypes are those with two identical 
alleles (two identical copies of DNA). Homozygous alleles are denoted with the same two colors 
(red) on each sister chromatid. A ROH is the presence of consecutive markers for homozygous 
alleles that occur throughout a region of DNA. This study hypothesized that normal DNA of 
cancer patients have ROH (indicated above by large regions of red at the same chromosomal 
location on both copies of DNA).  The control population is hypothesized to not harbor ROH at 
susceptibility loci. 
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Figure 3:  Skts5 Locus. Skts5 locus on mouse chromosome 12 has homologous regions to 
human chromosome 7p21 and 7q31.  These areas on human chromosome 7 are of interest in this 
study. 
 
 
 
Figure 4: Chromosome 11 Susceptibility Loci. SNPs on 11q23-11q24 were found to exhibit 
somatic allelic imbalance in SCC tumors, and this region was identified as a new SCC tumor 
susceptibility locus.  These loci are regions of interest in this study. 
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CHAPTER 2 
STUDY RATIONALE AND HYPOTHESIS 
Runs of homozygosity, ROH, is a relatively new concept in cancer genetics.  Previous 
studies have found that homozygosity occurs at a higher frequency in normal DNA of various 
cancers, such as breast and prostate cancer6.  With the presence of extended homozygous tracts 
and the numerous cancer susceptibility genes in the genome, there is a high likelihood that ROH 
will occur at loci of cancer susceptibility genes.  Homozygous segments that increase cancer risk 
can arise from a variety of causes, such as genomic changes that result in recessive mutant 
cancer genes, biallelic mutations in highly penetrant dominant cancer genes, or low-penetrance 
cancer predisposition SNPs7.  One study found an increased frequency of homozygosity at 114 
loci in normal DNA from individuals with breast and prostate cancer, and head and neck 
squamous cell carcinomas.  However, ROH has not been studied in cutaneous SCC. 
The purpose of this project was to see if this newly described phenomenon of ROH 
applies to skin cancer.  The aim of this study was to determine whether these stretches of 
homozygosity are more common in normal genomic DNA from individuals with skin cancer 
than in controls.  There are two hypotheses for this project: 1) Runs of homozygosity are 
common in individuals with skin cancer, specifically squamous cell carcinoma (SCC) and that 2) 
certain SNPs are associated with risk of SCC.  To test these hypotheses, normal DNA from SCC 
patients (cases) and non-cancer patients (controls) were genotyped at specific SNPs located on 
chromosome 7 and 11 to look for the presence of homozygosity.  The goal of this study was to 
identify candidate cancer-promoting chromosomes and regions in the genome that contained 
either ROH or significant SNPs associated with SCC, and to determine the effect of 
homozygosity on cancer predisposition and development. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Patients and Control Samples 
Samples in this study consisted of SCC patients (cases) and non-cancer (control) 
individuals.  All patients and individuals signed informed consent.  SCC patients were 
ascertained through OSU Medical Center dermatology clinics.  Genomic DNA from both SCC 
patients and non-cancer patients were used.  Collected samples consisted of 185 controls and 277 
cases.  Controls included in this study were samples in the Columbus-based Controls Collection 
from the Human Cancer Genetic Sample bank.  All controls were age and gender matched to 
cases, and the average age was 66 years for both sample groups. 
 
3.2 Genotyping 
We quantitatively genotyped DNA from both case and control samples using 
MassARRAY Iplex gold genotyping technology from Sequenom.  Sequenom uses a primer oligo 
base extension assay with matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry.  This technology allows for multiplex analysis of many polymorphisms at once 
and uses a quantitative approach to determine genotypes. 
This SNP genotyping assay is based on a polymerase chain reaction (PCR), followed by a 
single base primer extension reaction.  Forward and reverse primers flanking SNPs are used first 
in a PCR to amplify the DNA.  Extension primers are then used to differentiate and determine 
the two alleles, or nucleotides, at each SNP.  These primers anneal to the DNA adjacent to the 
SNP, and through a single base extension step, an extra nucleotide complementary to the SNP is 
added.  Since nucleotides differ in mass, the DNA fragments can therefore be separated by mass 
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using mass spectrometry.  The proportion of nucleotides at each SNP was determined and used 
to indicate a homozygous or heterozygous state.  SNP genotypes composed of both Allele 1 and 
Allele 2 are heterozygous, and SNP genotypes with two copies of Allele 1 or Allele 2 are 
homozygous.  When Sequenom detects only one mass for the DNA fragments, it indicates that 
the alleles are the same and the genotyping call is homozygous.  When Sequenom detects two 
different masses within the DNA fragments, it indicates that the alleles are different and the 
genotyping call is heterozygous (Figure 4).   
RealSNP Sequenom designer software was used to design nucleotide primer sets and 
multiplexing mixes for SNPs tagging in genes on chromosomes 7 and 11 (Supplemental Table 1 
and 2).  Chromosome 7 and 11 were chosen for this study because previous results in the lab 
suggested that they house SCC susceptibility genes and are implicated in disease progression.  
Chromosome 7 maps to Skts5 in mouse and chromosome 11 shows preferential allelic imbalance 
in SCC tumors.  A total of 123 SNPs mapping to chromosome 7 and 11 were genotyping by 
Sequenom Mass ARRAY (Table 1).  Fifty-one SNPs mapped to chromosome 7 and 72 SNPs 
mapped to chromosome 11.  Individual primers were designed for each SNP of interest. 
 
3.3 Sequencing 
Following genotype analysis, a number of SNPs were out of Hardy-Weinberg 
equilibrium.  DNA sequencing was conducted to further evaluate the genotyping results for 14 of 
these SNPs.  The Sequenom primers were sequenced to test the presence of biases, such as DNA 
mutations or polymorphisms in the DNA complementary to the Sequenom Primers.  This could 
affect the primer’s ability to bind to the DNA sequence around the SNP.  PCR primers were 
designed to sequence the Sequenom primer binding regions at 14 different SNPs on chromosome 
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7 and 11 (Supplemental Table 3).  PCR was performed using 15ng of input DNA using Taq 
DNA polymerase (Qiagen, Valencia, California), 1µM forward and reverse primers, 1x Q-
solution (Qiagen, Valencia, California), 1x  PCR buffer (Quiagen, Valencia, California), and 
500µM  dNTPs (Denville Scientific, Metuchen, New Jersey) in a final volume of 20µl for 35 
cycles at 58ºC.  PCR product were run on a 1% agarose gel and visualized by ethidium bromide 
staining. 
PCR products were treated with Exo/SAP-iT to remove single stranded DNA (USB, 
Cleveland, OH).  Automated sequencing of PCR products was conducted on an ABI 3700 by 
standard methods through the OSU Nucleic Acids Shared Resource.  Forward and reverse 
sequences were analyzed using SeqMan/DNAstar 3.0 (www.dnastar.com) to identify mutations 
and polymorphisms.   
 
3.4 Statistical Analysis 
One aim of this study was to look at the distribution of alleles and genotypes within the 
case and control population, and to determine their adherence to Hardy-Weinberg Equilibrium 
(HWE).  This principle states that both allele and genotype frequencies in a population remain 
constant, unless disturbances occur that influence this equilibrium.  Constant frequencies depend 
on random mating, no mutation, no migration or emigration, large population size, and no natural 
selection.  This is an ideal population state that provides a way to measure genetic changes in an 
affected or diseased population. 
This study analyzed the observed genotypes of cancer and non-cancer patients with 
expected genotypes.  We wanted to determine whether the sample population was consistent 
with or deviated from HWE (Figure 5).  Similar observed and expected genotype frequencies are 
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considered to be within HWE, and varying observed and expected genotype frequencies 
represented a deviation from HWE.  Testing for HWE deviations was performed by a chi (χ2) 
square analysis.  A p-value for each SNP was determined for significance (p<0.01).  All 
genotype data from Sequenom were denoted as observed genotype frequencies (Supplemental 
Table 4-7).  From these, the allele frequencies were calculated and used to determine the 
expected genotype frequencies under HWE.  This was done by using the Hardy-Weinberg 
equations.  Comparison of the observed and expected genotype frequencies can reveal any 
deviations from HWE.  We expected the controls to stay within HWE and the cases (diseased) to 
deviate from equilibrium.   
To address our first hypothesis of the presence of ROH, the percentage of homozygous 
genotypes at each SNP was calculated.  We compared the percent heterozygosity and 
homozygosity for both the cases and controls, and looked at the SNP locations to identify the 
presence of ROH.  In this study, a ROH was defined as a stretch of at least 12 or more 
consecutive SNPs with high frequencies of homozygous genotypes.   
 Our second hypothesis was that certain SNPs are associated with SCC risk.  The odds 
ratio (OR), a statement of the likelihood of an event, and a 95% confidence interval (CI) were 
computed for each SNP.  An OR was calculated for both homozygous and heterozygous 
genotypes.  Upper and lower confidence intervals for the OR were also analyzed for significance.  
Significant ORs with confidence intervals greater or less than 1.0 indicate association between 
genotype and an event.  The event in this study is the SCC disease state.  An OR of 1.0 implies 
that an individual has an equal likelihood of developing or not developing SCC.  SNP ORs with 
confidence intervals greater than 1.0 indicate that the genotype causes an increased risk of SCC.  
ORs of less than 1.0 indicate that the genotype acts as a potential protective factor for SCC. 
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Figure 4: Sequenom iPlex Technology: MassARRAY Iplex gold genotyping technology uses a 
primer oligo base extension assay and flight mass spectrometry.  Based on the differential 
masses of the alleles (nucleotides) of the SNPs, the genotype can be determined.  One peak 
indicates DNA fragments of the same mass, denoting two identical alleles and a homozygous 
genotype.  Two peaks indicate fragments of differential mass, denoting the SNP as heterozygous.   
 
 
 
Figure 5: Hardy-Weinberg Equilibrium (HWE): HWE occurs when genotype and allele 
frequencies remain constant in the absence of disturbing influences.  p and q are the frequencies 
of allele 1 and 2 respectively.  p2 and q2 are the frequencies of the two homozygotes, and 2pq is 
the frequency of heterozygotes.  Equations are for populations in HWE, and the graph depicts the 
relationship between the allele and genotype distributions. 
 
Equations: 
p + q = 1 
p2 + 2pq + q2 = 1 
Homozygote   Heterozygote Homozygote 
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Table 1: SNPs of Interest 
 
SNP Gene Location 
rs10225248 Between ARL4A and ETV1 chr7:13214211 
rs2214867 Between ARL4A and ETV1 chr7:13701250 
rs6461065 Between ETV1 and DGKB chr7:14072405 
rs10486048 DGKB chr7:14210927 
rs2237298 AHR chr7:17314644 
rs2158041 AHR chr7:17334945 
rs7811989 AHR chr7:17337888 
rs2040623 AHR chr7:17347187 
rs801759 HDAC9 chr7:18510723 
rs11543651 HDAC9 chr7:18557184 
rs801763 HDAC9 chr7:18567890 
rs2520456 HDAC9 chr7:18581044 
rs3807917 HDAC9 chr7:18583439 
rs2520458 HDAC9 chr7:18589454 
rs2073973 HDAC9 chr7:18591198 
rs2695029 HDAC9 chr7:18593148 
rs2695027 HDAC9 chr7:18598205 
rs3213615 HDAC9 chr7:18600332 
rs2239926 HDAC9 chr7:18603086 
rs2704284 HDAC9 chr7:18612153 
rs1405618 HDAC9 chr7:18616611 
rs1554774 HDAC9 chr7:18627934 
rs3801986 HDAC9 chr7:18631105 
rs7796078 HDAC9 chr7:18639763 
rs212664 HDAC9 chr7:18729642 
rs17349342 HDAC9 chr7:18781998 
rs7783171 HDAC9 chr7:18795321 
rs12540224 HDAC9 chr7:18797014 
rs6974011 HDAC9 chr7:18804988 
rs12699991 HDAC9 chr7:18827285 
rs2520362 HDAC9 chr7:18830424 
rs2073964 HDAC9 chr7:18844675 
rs6461387 HDAC9 chr7:18864830 
rs12700003 HDAC9 chr7:18872391 
rs10237366 HDAC9 chr7:18882084 
rs17350355 HDAC9 chr7:18895028 
rs11764843 HDAC9 chr7:18901835 
rs10247238 HDAC9 chr7:18909429 
rs726116 HDAC9 chr7:18918611 
rs6969316 HDAC9 chr7:18922212 
rs6947529 HDAC9 chr7:18925467 
rs726805 HDAC9 chr7:18929213 
rs2158768 HDAC9 chr7:18936675 
rs1034805 HDAC9 chr7:18944178 
rs2853552 HDAC9 chr7:18946792 
rs10486329 HDAC9 chr7:18960717 
rs17140399 HDAC9 chr7:18965129 
rs7808451 HDAC9 chr7:18969411 
rs17140423 HDAC9 chr7:18974409 
rs6968777 HDAC9 chr7:18977874 
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rs2526633 HDAC9 chr7:18997276 
rs2587550 Between ANKK1 and DRD2 chr11:112778135 
rs6276 DRD2 chr11:112786607 
rs2734839 DRD2 chr11:112791450 
rs4245147 DRD2 chr11:112823217 
rs4938023 Between DRD2 and TMPRSS5 chr11:112880057 
rs4534613 Between DRD2 and TMPRSS5 chr11:112891253 
rs12361261 Between DRD2 and TMPRSS5 chr11:112891829 
rs7115090 Between DRD2 and TMPRSS5 chr11:112920930 
rs11214677 Between DRD2 and TMPRSS5 chr11:112982291 
rs4471464 Between DRD2 and TMPRSS5 chr11:113009292 
rs1509513 Between DRD2 and TMPRSS5 chr11:113010123 
rs12802646 Between DRD2 and TMPRSS5 chr11:113047669 
rs7933647 Between DRD2 and TMPRSS5 chr11:113055939 
rs11214716 ZW10 chr11:113123185 
rs2459976 ZW10 chr11:113148203 
rs6589396 Between ZW10 and AX748073 chr11:113151087 
rs1713676 AX748073 chr11:113165786 
rs7111825 USP28 chr11:113201863 
rs11214741 USP28 chr11:113223807 
rs2097078 Between USP28 and HTR3b chr11:113258726 
rs6589400 Between USP28 and HTR3b chr11:113272935 
rs1176746 HTR3b chr11:113307811 
rs17626940 Between HTR3a and ZBZTB16 chr11:113397918 
rs238935 ZBZTB16 chr11:113471635 
rs238914 ZBZTB16 chr11:113489319 
rs238903 ZBZTB16 chr11:113493997 
rs763857 ZBZTB16 chr11:113502545 
rs1997547 ZBZTB16 chr11:113507954 
rs2106234 ZBZTB16 chr11:113513263 
rs648181 ZBZTB16 chr11:113552800 
rs655988 ZBZTB16 chr11:113577575 
rs371267 ZBZTB16 chr11:113608225 
rs612592 RPUSD4 chr11:125579034 
rs676982 RPUSD4 chr11:125580429 
rs624590 FAM118B chr11:125588547 
rs695077 FAM118B chr11:125593159 
rs11220409 FAM118B chr11:125601174 
rs17656 SRPR chr11:125638392 
rs499205 SRPR chr11:125639829 
rs638766 SRPR chr11:125639908 
rs667627 FOXRED1 chr11:125652907 
rs591163 Between FOXRED1 and TIRAP chr11:125653642 
rs8177374 TIRAP chr7:125668053 
rs8177376 Between TIRAP and DCPS chr11:125668822 
rs1786704 Between TIRAP and DCPS chr11:125670967 
rs648710 DCPS chr11:125681586 
rs586566 DCPS chr11:125704828 
rs240537 DCPS chr11:125718301 
rs7937122 AK096370 chr11:125729658 
rs11220473 ST3GAL4 chr11:125776848 
rs582037 ST3GAL4 chr11:125783285 
rs2230279 ST3GAL4 chr11:125783285 
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rs752806 Between ST3GAL4 and KIRREL3 chr11:125798449 
rs7925175 KIRREL3 chr11:125844645 
rs1943528 KIRREL3 chr11:125882665 
rs9971527 KIRREL3 chr11:125894275 
rs612841 KIRREL3 chr11:125914444 
rs625496 KIRREL3 chr11:125917216 
rs6590224 KIRREL3 chr11:126065650 
rs4935987 KIRREL3 chr11:126107596 
rs10893564 KIRREL3 chr11:126131899 
rs7127398 KIRREL3 chr11:126133006 
rs1946050 KIRREL3 chr11:126162173 
rs11220621 KIRREL3 chr11:126182338 
rs1106804 KIRREL3 chr11:126194653 
rs7110377 KIRREL3 chr11:126231423 
rs10750355 KIRREL3 chr11:126261121 
rs10893604 KIRREL3 chr11:126275543 
rs1628588 KIRREL3 chr11:126293260 
rs1793668 KIRREL3 chr11:126298028 
rs2508557 Between KIRREL3 and PRR10 chr11:126377995 
rs7941136 PRR10 chr11:126379370 
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CHAPTER 4 
RESULTS 
This project is a case-control study that focuses on the genetics of squamous cell 
carcinoma.  Three different ideas and concepts were analyzed for the regions on chromosome 7 
and 11.  The first was to determine the frequencies of homozygosity and heterozygosity in 
genomic DNA from cases and controls.  We hypothesized that we would find lower frequencies 
of heterozygosity (and consequently higher frequencies of homozygosity) in the case population 
compared to controls.  From this, we determined if SNPs with high homozygosity levels 
occurred in a consecutive sequence that would indicate the presence of ROH.  Secondly, we 
were interested in looking at Hardy-Weinberg Equilibrium and comparing the genotype and 
allele distribution in both the case and control sample populations.  Lastly, we wanted to identify 
SNPs that were associated with increased risk or resistance to the disease by calculating the OR 
for homozygotes and heterozygotes.  An OR greater than one indicates that the SNP has a role in 
SCC susceptibility, and an OR less than one indicates that the SNP has a protective and resistant 
effect. 
 Two rounds of genotyping were conducted.  In the first round, 123 SNPs (51 from 
chromosome 7 and 72 from chromosome 11) were genotyped to gather preliminary results and 
identify any significant trends in the data.  Ten SNPs from chromosome 7 and 20 SNPs from 
chromosome 11 were then chosen for a second round of genotyping in additional samples to 
increase sample size and validate previous results.  These SNPs were chosen because they 
exhibited significant HWE p-values in the case population and significant OR suggesting SCC 
risk and protection.  We wanted to see the trends from the initial round of genotyping to continue 
in a larger sample size and to reach statistical significance for risk.  The second round of 
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genotyping was also done to validate the experimental method and confirm the consistency of 
genotype calls made by Sequenom. 
 
4.1 Chromosome 7 
4.1.1 Initial Genotyping Studies 
 We initially genotyped 96 control and 172 case DNA samples by Sequenom at 51 SNPs 
on chromosome 7 to identify regions of ROH and SNPs that deviated from Hardy-Weinberg 
Equilibrium in the case population (Table 2).  The SNPs map across a region of 112 Mb of DNA. 
The average percent heterozygosity across all SNPs was 39.93% and 42.46% within the case and 
control samples respectively.  Overall frequencies of heterozygosity were similar, and only a few 
SNPs exhibited significant differences between the cases and controls.  The largest ROH we 
found contained 16 adjacent SNPs mapping to a 120 kb region.  Interestingly, no significant and 
unique ROH was identified in the case population for this region.   
A few SNPs exhibited differential genotype distribution between the two populations.  
The patient population was significantly out of HWE in (p<0.01) at rs1269991 and the control 
population deviated from HWE (p<0.01) at rs2237298.  Three of the 51 SNPs (5.88%) were 
calculated to have an OR for increased risk in the homozygous genotype state, while one of these 
three also showed increased risk for SCC in the heterozygous state (rs3807917, rs2695029, 
rs3213615).  One SNP was identified to be protective in the heterozygous state (rs2520458), and 
one SNP showed resistance to SCC in the homozygous state (rs6974011).  Despite the 
insignificant differences in average percentage heterozygosity between the cases and controls 
across all of the tested SNPs, one region of interest was identified.  A 17kb region containing 
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four SNPs exhibited significant varying genotype and allele frequencies, heterozygosity and 
homozygosity, or ORs for risk or protection between the cases and controls. 
 
4.1.2 Validation Genotyping for Selected SNPs 
Ten SNPs were genotyped in a total of 220 cases and 138 controls for validation of initial 
results. Of the interesting SNPs chosen for further genotyping, four SNPS continued to exhibit 
significant characteristics (rs3807917, rs2520458, rs6974011, rs1269991) (Table 3).  The 
average percent heterozygosities for these SNPs were 31.98% in the cases and 35.41% in the 
controls.  Collectively across chromosome 7, there was no significant difference between 
heterozygosity between cases and controls, although individual SNP differences were observed.  
The case population exhibited genotypic deviations from HWE (p<0.01) at one SNP 
(rs1269991). 
Only one SNP, rs3807917, had an OR > 1 (OR: 2.30, CI: 1.11-4.74, p=0.01), indicating 
risk in the homozygous state of TT.  With additional control and case samples, the percent 
heterozygosities were 43.48% (50/115) in the cases and 53.62% (74/138) in the controls. 
The SNPs rs2520458 and rs1269991 were calculated to have OR < 1 for heterozygotes.  
This suggests that having a heterozygous genotype at these SNPs is protective of SCC.  
Interestingly, for rs6974011, both the OR for heterozygotes TG (OR: 0.40, CI: 0.17-0.94) and 
homozygotes GG (OR: 0.36, CI: 0.16-0.83) were below 1.  The ‘G’ allele acts in a dominant 
manner, and appears to confer resistance to SCC whenever it is present, either in a heterozygote 
or homozygous state. 
Four SNPs appear to be validated and trends seen from initial genotyping were 
reinforced.  rs3807917 continued to have an OR > 1 (CI: 1.11-4.74), suggesting increased risk 
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for SCC in the homozygous state, and rs2520458 continued to exhibit OR < 1 (CI: 0.34-0.89), 
indicating protection in the heterozygous state.  With additional samples, rs12699991 had a 
significant HWE p-value in the case population and was protective in the heterozygous state.  
These SNPs are located in Hdac9, suggesting this gene to be involved in SCC development and 
susceptibility. 
 
4.2 Chromosome 11 
4.2.1 Initial Genotyping Studies 
 Seventy-two SNPs on chromosome 11 were initially genotyped by Sequenom in 148 case 
and 35 control DNA samples (Table 4).  All SNPs together extend across 114 Mb of DNA. The 
average percent heterozygosity of the SNPs was 33.57% and 39.79% in the case and control 
samples respectively.  Percent heterozygosities were fairly similar in both the cases and controls, 
and only a few SNPs exhibited noticeable differences between populations.  The longest ROH in 
the cases contained 20 adjacent SNPs mapping to a 220kb region.  However, no ROH were 
identified to be significant in the case population because similar regions of homozygosity were 
observed in the control population. 
 A number of SNPs snowed noticeably different patterns of percent heterozygosity 
between cases and controls.  The case population was out of HWE (p<0.01) at ten SNPs 
(13.89%) and the control population deviated from HWE (p<0.01) at four SNPs (5.55%).  Four 
SNPs (5.55%) were calculated to have significant OR for increased risk in the homozygous state 
(rs2734839, rs624590, rs591163, rs752806).  The SNP rs591163 also exhibits increased risk in 
the heterozygous state.  Other SNPs associated with increased risk in the heterozygous state are 
rs586566 and rs240537.  Four SNPs (5.55%) were calculated to have significant OR for 
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resistance in the homozygous state (rs1176746, rs676982, rs638766 and rs1793668).  Five SNPs 
(6.94%) had significant ORs for resistance in the heterozygous state (rs12361261, rs752806, 
rs7127398, rs1793668, rs7941136). 
 
4.2.2 Validation Genotyping for Selected SNPs 
Twenty SNPs on chromosome 11 were chosen for further genotyping in 277 cases and 
185 controls.  The majority of them exhibited some sort of significant characteristic, including 
genotype distributions out of HWE (p<0.01), or significant OR for risk in either heterozygotes or 
homozygotes (Table 5).  Similar frequencies of homozygosity and heterozygosity were found in 
both the cases and controls; the average percent heterozygosity across these 20 SNPs was 
34.41% and 40.12% in the case and control population respectively.  The case population 
genotype distribution was out of HWE for eight SNPs (p<0.01), and the control population’s 
distribution deviated from HWE at one SNP.  Two SNPs (10.53%) show significant OR for 
increased risk in homozygotes (rs2734839 and rs752806) and no SNPs showed an increase risk 
in heterozygotes.  Six SNPs (26.32%) showed significant OR for resistance to SCC in 
heterozygotes (rs2587550, rs2734839, rs1509513, rs10893564, rs7127398, rs1793668).  SNP 
rs1793668 was protective in both the heterozygous and homozygous states, and other SNPs 
associated with SCC resistance in the homozygous state were rs1176746 and rs11220409. 
The SNP rs2734839 continued to show similar results as those seen in the first round of 
genotyping.  With a larger sample size, the case population continued to exhibit genotype 
distributions that deviated from HWE (p<0.01).  Low rates of heterozygosity (and conversely 
high rates of homozygosity) were seen at this SNP (16.13% (25/155) in cases and 43.56% 
(71/163) in controls).  Cases had three times more homozygotes (GG) than controls while the 
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controls had three times more heterozygotes (AG) than the cases (44.52% and 15.95% GG 
homozygotes in cases and controls respectively).  The OR calculations for rs2734839 show that 
the heterozygous genotype confers resistance (OR: 0.38, CI: 0.18-0.84) while the homozygous 
genotype of GG confers an increased risk of SCC (OR: 2.87, CI: 1.62-5.08). 
Fourteen SNPs on chromosome 11 were validated.  Many continued to exhibit the same 
significant trends as in the initial round of genotyping.  With the additional case and control 
samples, other SNPs with p<0.01 for HWE and significant OR were noted.  Significant SNPs 
were found within the genes DRD2 and KIRREL3, suggesting these genes as contributors to SCC 
susceptibility and resistance. 
 
 
4.3 Sequencing of Sequenom Primers 
 
For some SNPs, the case or control population’s genotype and/or allele distribution were 
significantly out of HWE.  A few SNPs exhibited disproportionate distributions of genotypes, 
where some populations contained little or none of a certain genotype.  We hypothesized that 
these distributions were caused by a possible polymorphisms or mutations within the DNA 
sequence where the Sequenom primers lay, affecting the accuracy of our results.  Primers that 
hybridize to regions containing polymorphisms may have difficulty annealing.  This then can 
possibly influence the fidelity of polymerization during the amplification or extension step. 
To test this hypothesis, we sequenced the DNA regions where the Sequenom primers lay 
for 14 SNPs.  We then compared the DNA sequences to determine if any polymorphisms or 
mutations are present.  We found that the Sequenom extension primer for rs801763 lay in a 
region on chromosome 7 that contained a polymorphism (an AA change to AG), suggesting that 
this was the reason why the particular SNP was out of HWE (Figure 7).  None of the other 
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primers for the other SNPs out of HWE appeared to contain polymorphism in the samples 
sequenced; thus we do not have an explanation for the disproportionate genotype distributions. 
 
 
 
 
Figure 7: Sequencing of Sequenom Primers.  Normal DNA sequence on top and DNA sample 
from the study on bottom.  Extension primer for SNP rs801763 lay in a chromosome 7 region 
containing a polymorphism from AA to AG (left box, R=AG).  The SNP is in the right box, Y 
indicating a genotype of TC. 
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Table 2: Chromosome 7 Initial Genotyping Results 
 
SNP # 
Cases 
# 
Controls 
HWE 
p-value 
Case 
HWE 
p-value 
Control 
% Het 
Case 
% Het 
Control 
OR 
Heterozygote 
(95% CI) 
OR  
Homozygote (95% 
CI) 
rs10225248 24 151 0.586 0.810 41.67 50.30 0.61 (0.23-1.56) 0.62 (0.18-2.21) 
rs2214867 16 130 0.341 0.432 37.50 46.15 0.48 (0.14-1.63) 0.47 (0.12-1.82) 
rs6461065 87 158 0.749 0.275 31.03 36.71 0.79 (0.45-1.39) 1.36 (0.35-5.26) 
rs10486048 85 155 0.766 0.911 22.35 19.35 1.27 (0.11-14.95) 1.06 (0.09-11.88) 
rs2237298* 21 116 0.519 0.008 52.38 27.59 2.06 (0.40-10.70) 0.67 (0.13-3.53) 
rs2158041* 32 147 0.279 0.445 51.16 25.17 0.99 (0.22-4.56) 0.29 (0.06-1.30) 
rs7811989 42 150 0.098 0.125 40.48 30.67 2.75 (0.56-13.45) 1.01 (0.20-4.94) 
rs2040623 85 160 0.114 0.026 24.71 30.63 0.70 (0.38-1.28) 0.54 (0.19-1.57) 
rs801759* 74 83 0.332 0.645 20.27 9.64 N/A (N/A) N/A  (N/A) 
rs11543651 18 123 0.130 0.018 22.22 30.89 0.74 (0.12-4.48) 1.18 (0.24-5.88) 
rs801763* 36 86 0.391 0.774 25.00 27.91 0.82 (0.34-2.00) 0.00 (N/A) 
rs2520456 87 156 0.586 0.379 34.48 44.23 0.80 (0.27-2.35) 1.23 (0.43-3.54) 
rs3807917* 22 141 0.011 0.134 22.73 51.77 0.41 (0.13-1.30) 3.43 (1.12-10.50) 
rs2520458* 85 159 0.087 0.046 35.29 52.20 0.53 (0.30-0.94) 1.35 (0.56-3.24) 
rs2073973 85 159 0.334 0.934 44.71 49.69 0.68 (0.25-1.32) 0.72 (0.35-1.49) 
rs2695029* 39 148 0.101 0.749 58.97 48.65 3.83 (1.08-13.62) 3.90 (1.03-14.80) 
rs2695027 39 146 0.639 0.591 38.46 45.89 0.60 (0.28-1.29) 0.43 (0.13-1.40) 
rs3213615* 26 153 0.249 0.868 38.46 43.14 1.23 (0.27-3.21) 4.06 (1.30-12.70) 
rs2239926 87 158 0.647 0.564 40.23 39.87 1.00 (0.31-3.22) 0.98 (0.31-3.11) 
rs270428 4 86 155 0.463 0.172 53.49 55.48 0.76 (0.40-1.43) 0.65 (0.29-1.43) 
rs1405618 24 154 0.586 0.503 33.33 44.16 0.71 (0.13-3.74) 1.14 (0.23-5.64) 
rs1554774 82 153 0.990 0.287 41.46 35.29 1.32 (0.75-2.33) 1.13 (0.42-3.04) 
rs3801986 21 135 0.505 0.462 57.14 52.59 1.06 (0.31-3.58) 0.80 (0.20-3.27) 
rs7796078 22 155 0.143 0.238 27.27 39.35 0.57 (0.20-1.58) 0.91 (0.24-3.52) 
rs212664 41 145 0.103 0.130 29.27 39.31 0.88 (0.28-2.81) 1.50 (0.51-4.43) 
rs17349342 42 143 0.801 0.371 47.62 51.05 0.58 (0.23-1.47) 0.43 (0.20-1.46) 
rs7783171 43 149 0.758 0.390 30.23 33.56 0.88 (0.42-1.85) 1.70 (0.30-9.75) 
rs12540224 85 156 0.554 0.694 52.94 50.64 0.94 (0.46-1.90) 0.77 (0.35-1.69) 
rs6974011* 15 125 0.447 0.842 40.00 44.00 0.26 (0.07-1.00) 0.17 (0.04-0.71) 
rs12699991* 85 156 0.008 0.729 34.12 49.36 0.56 (0.31-1.02) 1.18 (0.57-2.45) 
rs2520362 43 150 0.878 0.048 51.16 58.00 0.86 (0.37-2.00) 1.29 (0.48-3.47) 
rs2073964 42 153 0.853 0.996 45.24 47.06 0.96 (0.24-2.72) 1.06 (0.27-3.02) 
rs6461387 20 114 0.257 0.242 35.00 54.39 0.51 (0.13-1.93) 1.19 (0.32-4.41) 
rs12700003 43 153 0.738 0.942 51.16 49.02 1.01 (0.47-2.15) 0.80 (0.29-2.21) 
rs10237366 85 155 0.629 0.422 49.41 51.61 1.15 (0.51-2.56) 1.37 (0.59-3.17) 
rs17350355 19 124 0.161 0.952 31.58 48.39 0.50 (0.13-1.95) 1.02 (0.28-3.72) 
rs11764843 21 135 0.071 0.405 28.57 45.18 0.47 (0.16-1.39) 0.92 (0.29-2.99) 
rs10247238 40 148 0.109 0.566 55.00 46.62 2.39 (0.51-11.28) 1.88 (0.39-9.05) 
rs726116 14 79 0.498 0.706 35.71 40.51 0.87 (0.25-3.01) 1.39 (0.24-7.98) 
rs6969316 42 153 0.997 0.407 45.24 36.60 0.88 (0.28-2.80) 0.56 (0.18-1.76) 
rs6947529 17 124 0.597 0.510 41.18 50.81 0.68 (0.22-2.09) 1.02 (0.24-4.41) 
rs726805 40 144 0.945 0.433 45.00 45.83 0.79 (0.37-1.68) 0.50 (0.17-1.49) 
rs2158768 41 150 0.183 0.474 39.02 46.67 0.75 (0.31-1.84) 1.05 (0.42-2.63) 
rs1034805 85 157 0.832 0.500 42.35 47.13 0.81 (0.47-1.42) 0.94 (0.38-2.33)  
rs2853552 21 147 0.990 0.122 42.86 34.01 1.49 (0.57-3.93) 1.19 (0.23-5.99) 
rs10486329 81 152 0.575 0.604 53.09 47.37 1.06 (0.53-2.12) 0.74 (0.34-1.61) 
rs17140399 24 151 0.367 0.804 54.17 46.36 2.14 (0.45-10.18) 1.78 (0.36-8.90) 
rs7808451 85 155 0.414 0.551 43.53 47.10 0.75 (0.42-1.36) 0.67 (0.32-1.43) 
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rs17140423 41 148 0.071 0.203 31.71 37.16 0.87 (0.40-1.88) 1.60 (0.58-4.41) 
rs6968777 85 150 0.414 0.496 43.53 45.33 0.94 (0.45-2.00) 1.02 (0.47-2.20) 
rs2526633 84 156 0.647 0.049 42.86 35.26 2.07 (0.76-5.69) 1.62 (0.60-4.37)  
*: SNPs chosen for validation genotyping 
 
 
 
Table 3: Chromosome 7 Validation Genotyping for Interesting SNPs 
 
SNP # 
Cases 
# 
Controls 
HWE 
p-value 
Case 
HWE 
p-value 
Control 
% Het 
Case 
%Het 
Control 
OR 
Heterozygote 
(95% CI) 
OR 
Homozygote 
(95% CI) 
rs2237298 103 127 0.066 0.094 32.04 35.43 1.00 (0.41-2.46) 1.20 (0.51-2.82) 
rs2158041 141 135 0.758 0.794 39.72 26.67 0.69 (0.20-2.41) 0.36 (0.11-1.20) 
rs801759 142 110 0.662 0.617 21.83 9.09 0.00 (N/A) 0.00 (N/A) 
rs801763 129 101 0.625 0.867 25.58 22.77 1.19 (0.64-2.19) 1.65 (0.29-9.27) 
rs3807917 115 138 0.162 0.189 43.48 53.62 0.92 (0.52-1.64) 2.30 (1.11-4.74) 
rs2520458 176 137 0.028 0.040 37.50 54.01 0.55 (0.34-0.89) 1.38 (0.64-2.97) 
rs2695029 134 131 0.305 0.964 43.28 49.62 1.13 (0.59-2.16) 1.81 (0.91-3.60) 
rs3213615 116 133 0.052 0.257 35.34 45.86 0.42 (0.42-1.22) 1.90 (0.78-4.63) 
rs6974011 78 127 0.038 0.669 37.18 40.94 0.40 (0.17-0.94) 0.36 (0.16-0.83) 
rs12699991 176 136 0.001 0.382 35.80 51.47 0.57 (0.35-0.94) 1.30 (0.67-2.52) 
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Table 4: Chromosome 11 Initial Genotyping Results 
 
SNP # 
Cases 
# 
Controls 
HWE 
p-value 
Case 
HWE 
p-value 
Control 
% Het 
Case 
%Het 
Control 
OR 
Heterozygote 
(95% CI) 
OR  
Homozygote 
 (95% CI) 
rs4938023 69 32 0.766 0.864 44.93 43.75 0.89 (0.24-3.32) 0.80 (0.21-3.01) 
rs11214677 76 32 0.808 0.837 51.32 50.00 0.72 (0.23-2.27) 0.53 (0.15-1.85) 
rs2587550* 49 32 0.009 0.656 24.49 40.63 0.53 (0.12-2.27) 1.14 (0.29-4.52) 
rs6276 76 32 0.230 0.706 32.89 43.75 0.53 (0.21-1.30) 0.41 (0.11-1.52) 
rs2734839* 56 33 <0.0005 0.305 0.00 54.55 0.00 (N/A) 10.00 (2.49-40.22) 
rs4245147 60 30 0.611 0.956 46.67 50.00 0.66 (0.21-2.02) 0.59 (0.17-2.04) 
rs4534613 43 31 0.415 0.686 41.86 45.16 0.96 (0.27-3.43) 1.16 (0.32-4.26) 
rs12361261* 42 6 <0.0005 0.624 2.38 66.67 0.05 (0.00-0.72) N/A (N/A) 
rs7115090 61 29 0.438 <0.0005 44.26 17.24 2.83 (0.85-9.40) 0.52 (0.18-1.51) 
rs4471464 67 31 0.831 0.366 50.75 58.06 0.87 (0.28-2.68) 1.32 (0.36-4.81) 
rs1509513* 15 27 0.022 0.795 20.00 51.85 0.24 (0.05-1.22) 1.14 (0.23-5.67) 
rs12802646 66 33 0.282 0.995 39.39 45.55 0.69 (0.18-2.60) 0.86 (0.23-3.21) 
rs7933647 8 1 0.719 0.317 37.50 100.00 0.00 (N/A) N/A (N/A) 
rs11214716 30 32 0.058 0.355 16.67 28.13 0.56 (0.16-1.91) N/A (N/A) 
rs2459976 48 33 0.486 0.127 54.17 33.33 2.70 (0.99-7.39) 1.52 (0.42-5.47) 
rs6589396 31 30 0.525 0.469 38.71 23.33 2.63 (0.84-8.19) N/A (N/A) 
rs1713676* 50 29 0.160 0.015 40.00 62.07 0.00 (N/A) 0.00 (N/A) 
rs7111825 65 30 0.068 0.584 33.85 40.00 0.78 (0.30-1.99) 1.06 (0.28-3.96) 
rs11214741 43 29 0.923 0.873 48.84 44.83 0.72 (0.18-2.81) 0.48 (0.12-1.98) 
rs2097078 69 30 0.286 0.642 34.78 23.33 0.49 (0.05-4.69) 0.25 (0.03-2.14) 
rs6589400 56 32 0.089 0.192 26.79 37.50 0.00 (N/A) 0.00 (N/A) 
rs1176746* 37 32 0.558 0.684 43.24 53.13 0.45 (0.16-1.27) 0.16 (0.03-0.94) 
rs17626940 62 28 0.083 0.423 19.35 28.57 1.00 (0.14-7.39) 1.74 (0.27-11.29) 
rs238935 66 32 0.982 0.628 33.33 31.25 1.47 (0.21-10.20) 1.37 (0.21-8.84) 
rs238914 48 31 0.703 0.939 41.67 45.16 1.90 (0.37-9.87) 2.56 (0.50-13.22) 
rs238903 72 33 0.453 0.396 51.39 48.48 1.33 (0.56-3.17) 2.60 (0.49-13.64) 
rs763857 75 32 0.748 0.384 44.00 53.13 0.58 (0.14-2.40) 0.80 (0.19-3.41) 
rs1997547 16 11 0.086 0.875 12.50 45.45 0.40 (0.02-10.02) 2.60 (0.14-50.05) 
rs2106234 61 32 0.150 0.837 32.79 50.00 0.40 (0.16-1.04) 0.45 (0.12-1.72) 
rs648181 36 19 0.018 0.161 25.00 31.58 0.64 (0.18-2.35) 0.64 (0.15-2.84) 
rs655988 39 31 0.228 0.853 30.77 32.26 0.30 (0.03-3.13) 0.29 (0.03-2.79) 
rs371267 40 30 0.071 0.020 30.00 23.33 1.40 (0.46-4.30) 0.98 (0.26-3.75) 
rs612592 68 32 0.748 0.419 33.82 25.00 1.68 (0.65-4.35) N/A (N/A) 
rs676982* 69 33 0.980 0.450 39.13 42.42 0.63 (0.25-1.56) 0.23 (0.06-0.87) 
rs624590* 33 32 0.175 0.344 21.21 40.63 1.88 (0.31-11.64) 7.00 (1.26-38.99) 
rs695077 50 30 0.777 0.543 34.00 20.00 0.00 (N/A) 0.00 (N/A) 
rs11220409* 40 30 0.013 0.122 30.00 33.33 0.45 (0.13-1.58) 0.32 (0.10-1.08) 
rs17656 30 20 0.524 0.717 30.00 15.00 2.68 (0.62-11.57) N/A (N/A) 
rs499205 74 33 0.863 0.770 33.79 33.33 0.99 (0.41-2.39) 0.65 (0.10-4.21) 
rs638766* 59 32 0.529 0.344 28.81 40.63 0.40 (0.15-1.06) 0.13 (0.03-0.59) 
rs667627 57 31 <0.0005 <0.0005 17.54 3.23 6.32 (0.76-52.52) 0.95 (0.30-3.00) 
rs591163* 75 21 0.028 0.501 41.67 42.86 8.89 (1.86-42.44) 10.67 (2.07-54.85) 
rs8177374 24 149 0.624 0.637 25.00 26.85 0.92 (0.34-2.59) 1.22 (0.13-11.12) 
rs8177376 89 33 0.392 0.400 33.70 18.18 2.28 (0.85-6.15) 0.91 (0.08-10.52) 
rs1786704 113 33 0.865 0.461 31.86 33.33 2.45 (0.48-12.68) 2.88 (0.59-13.99) 
rs648710 40 26 <0.0005 <0.0005 2.50 3.85 0.92 (0.05-16.50) 1.77 (0.62-5.01) 
rs586566* 77 33 0.729 0.400 35.06 15.15 3.12 (1.07-9.09) 1.44 (0.26-7.98) 
rs240537* 78 31 0.206 0.616 43.59 22.60 2.72 (1.04-7.12) 1.68 (0.17-17.13) 
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rs7937122 106 33 0.438 0.930 52.83 48.45 1.31 (0.55-3.12) 1.35 (0.41-4.45) 
rs11220473 60 29 0.895 0.170 48.57 62.07 0.60 (0.22-1.67) 1.11 (0.27-4.51) 
rs582037 92 33 0.958 0.171 44.57 36.36 2.39 (0.75-7.63) 2.05 (0.66-6.41) 
rs2230279 108 32 0.064 0.083 46.30 46.88 1.05 (0.47-2.32) N/A (N/A) 
rs752806* 51 31 <0.0005 0.437 7.84 54.84 0.13 (0.03-0.50) 4.03 (1.10-14.78) 
rs7925175 54 30 0.433 0.794 40.74 53.33 0.92 (0.35-2.40) 1.08 (0.27-4.29) 
rs1943528 57 32 0.321 0.065 38.60 28.13 1.53 (0.39-5.95) 0.94 (0.26-3.33) 
rs9971527 70 33 0.577 0.632 31.43 42.42 0.50 (0.20-1.23) 0.25 (0.06-1.08) 
rs612841 76 32 0.212 0.258 42.11 56.25 0.31 (0.08-1.22) 0.43 (0.11-1.78) 
rs625496 77 32 0.600 0.614 45.45 53.13 0.74 (0.29-1.86) 1.00 (0.29-3.49) 
rs6590224* 41 153 0.713 0.002 39.02 21.57 1.21 (0.33-4.47) 0.48 (0.14-1.67) 
rs4935987 40 35 0.800 0.554 45.00 54.29 0.95 (0.26-3.48) 1.60 (0.40-6.36) 
rs10893564* 52 32 0.005 0.591 9.62 21.88 0.38 (0.11-1.33) 1.07 (0.09-12.37) 
rs7127398* 41 31 0.262 0.081 34.15 61.29 0.33 (0.12-0.93) 1.14 (0.19-6.89) 
rs1946050 33 24 0.009 0.221 24.24 33.33 0.67 (0.20-2.26) 1.17 (0.28-4.87) 
rs11220621 58 33 0.209 0.602 39.66 48.48 0.39 (0.09-1.63) 0.47 (0.11-1.97) 
rs1106804 30 31 0.288 0.230 36.67 48.39 0.79 (0.27-2.28) 5.36 (0.55-51.71) 
rs7110377 13 10 <0.0005 0.577 0.00 30.00 0.00 (N/A) 0.00 (N/A) 
rs10750355 33 33 0.036 0.602 30.30 48.48 0.23 (0.05-1.10) 0.40 (0.09-1.83) 
rs10893604 72 32 0.346 0.684 41.67 53.12 0.88 (0.28-2.78) 1.67 (0.49-2.71) 
rs1628588 71 33 0.450 0.707 45.07 51.51 0.59 (0.18-1.88) 0.65 (0.19-2.25) 
rs1793668* 62 29 <0.0005 0.139 14.52 20.69 0.17 (0.03-1.00) 0.19 (0.04-0.88) 
rs2508557* 53 32 0.291 0.039 41.51 31.25 0.99 (0.33-2.93) 0.38 (0.12-1.17) 
rs7941136* 51 32 0.674 0.540 29.41 50.00 0.35 (0.13-0.90) 0.12 (0.01-1.30) 
*: SNPs chosen for validation genotyping 
 
 
 
Table 5: Chromosome 11 Validation Genotyping for Interesting SNPs 
 
SNP # 
Cases 
# 
Controls 
HWE 
p-value 
Case 
HWE 
p-value 
Control 
% Het 
Case 
% Het 
Control 
OR 
Heterozygote 
(95% CI) 
OR 
Homozygote 
(95% CI) 
rs2587550 157 166 0.001 0.514 30.57 43.98 0.39 (0.18-0.84) 0.64 (0.30-1.36) 
rs2734839 155 163 <0.0005 0.351 16.13 43.56 0.38 (0.21-0.68) 2.87 (1.62-5.08) 
rs12361261 62 119 <0.0005 <0.0005 1.61 2.52 0.62 (0.06-6.14) 0.86 (0.31-2.40) 
rs1509513 117 168 0.223 0.368 40.17 52.38 0.52 (0.31-0.88) 0.60 (0.29-1.22) 
rs1713676 149 164 0.027 0.631 40.94 51.83 0.62 (0.36-1.07) 0.92 (0.50-1.69) 
rs1176746 132 163 0.979 0.456 40.91 44.79 0.70 (0.43-1.14) 0.38 (0.18-0.84) 
rs676982 166 168 0.084 0.036 33.73 33.33 1.00 (0.63-1.60) 0.89 (0.43-1.85) 
rs624590 140 165 0.004 0.064 27.14 33.94 0.82 (0.36-1.87) 1.16 (0.54-2.5) 
rs11220409 110 137 0.549 0.582 43.64 38.69 0.40 (0.15-1.05) 0.26 (0.10-0.68) 
rs638766 160 168 0.009 0.048 28.75 33.93 0.76 (0.47-1.23) 0.78 (0.37-1.64) 
rs591163 144 158 0.388 0.016 41.67 33.54 1.19 (0.58-2.47) 0.80 (0.40-1.63) 
rs586566 177 175 0.128 0.500 33.33 32.57 1.09 (0.69-1.71) 1.57 (0.68-3.66) 
rs240537 174 169 0.845 0.901 40.80 36.09 1.27 (0.81-1.98) 1.42 (0.59-3.39) 
rs752806 152 172 0.004 0.718 38.16 48.26 0.89 (0.52-1.50) 1.82 (1.01-3.27) 
rs6590224 140 135 0.423 0.711 34.29 25.93 0.55 (0.16-1.89) 0.34 (0.10-1.13) 
rs10893564 134 169 <0.0005 0.722 14.93 28.40 0.46 (0.26-0.82) 2.21 (0.65-7.54) 
rs7127398 39 31 0.215 0.081 33.33 61.29 0.33 (0.12-0.91) 1.19 (0.20-7.23) 
rs1793668 164 165 0.002 0.815 35.37 40.00 0.40 (0.19-0.82) 0.40 (0.20-0.81) 
rs2508557 150 173 0.686 0.203 46.67 45.09 0.85 (0.51-1.40) 0.56 (0.30-1.04) 
rs7941136 139 159 0.630 0.343 31.65 32.08 0.93 (0.57-1.52) 0.43 (0.13-1.42) 
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CHAPTER 5 
 
DISCUSSION 
 
 The genetic basis of susceptibility to SCC has yet to be determined.  Through genome 
wide association studies, the whole genome can be scanned for genetic abnormalities within 
disease populations.  Through these kinds of studies, allelic imbalance and loss of heterozygosity 
can be identified in cancers, leading to the elucidation of susceptibility loci and candidate genes.   
 Additionally, ROH is thought to be implicated for multiple diseases.  ROH is 
characterized by the presence of consecutive homozygous markers, such as SNPs.  ROH has 
been identified in a few cancers, such as breast and prostate cancer.  The presence of ROH in 
cancer patients may indicate its influence on cancer predisposition at the genetic level. 
 The hypotheses for this study were to determine if ROH are common in individuals with 
skin cancer (SCC), and to identify potential SNPs that are associated with SCC risk.  Normal 
DNAs were ascertained from cancer patients (cases) and non-cancer individuals (controls) and 
genotyped at 123 SNPs by Sequenom Technology.  These SNPs were hand-picked at regions on 
chromosome 7 and chromosome 11 that have been previously identified as potential candidate 
regions for SCC susceptibility genes.  Regions on human chromosome 7 mapped to the 
susceptibility locus Skts5 on mouse chromosome 12.  The regions of 11q23-11q24 on 
chromosome 11 have been previously implicated in SCC susceptibility based on preferential 
allelic imbalance studies.  
 Two rounds of Sequenom genotyping were conducted.  Initially, 53 SNPs mapping to 
chromosome 7 and 70 SNPs mapping to chromosome 11 were genotyped.  Frequencies of 
heterozygosity, HWE and genotype distribution, and odds OR for SCC risk were calculated for 
both the case and control populations.  After initial genotyping experiments, ten SNPs from 
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chromosome 7 and 20 SNPs from chromosome 11 were chosen for further genotyping to validate 
the results by increasing the sample size.  With a larger sample size, we looked to confirm our 
previous results and see the same trends in heterozygosity, variations in genotypic distributions, 
and odds ratio for SCC risk or protection as before.   
 
5.1 Chromosome 7 
Overall, the percentages of heterozygosity in cases and controls were similar and showed 
no significant differences across all 53 SNPs on chromosome 7.  Additionally, no ROH were 
identified to be significant and unique to just the case population.  The three SNPs rs2520458, 
rs6974011, rs12699991 were identified as candidate protective SNPs, and the rs3807917 was 
found to cause an increased risk of SCC. 
 After secondary genotyping, we found two regions of particular interest that were within 
and around the gene Hdac9 (Figure 8).  Hdac9 encodes the enzyme histone deacetylase 9.  
Histones are important in transcriptional regulation, cell cycle progression, and developmental 
events.  The acetylation and deacetylation of histones can alter chromosome structure, thus 
affecting a transcription factor’s access to DNA.   
The first region in Hdac9 contains two significant SNPs (rs3807917 and rs2520458) and 
maps to a 6kb region on chromosome 7.  We hypothesized that the cases would have a lower 
percentage of heterozygosity (and a higher proportion of homozygous alleles), and found that the 
case population experienced a 1.33 decrease in heterozygosity in this region (53.82% of controls 
and 40.49% of cases).  SNP rs3807917 was calculated to have an OR of 2.3 (CI: 1.11-4.74), 
indicating that the homozygous genotype of TT causes an increased risk of SCC.  The SNP 
rs2520458 was identified to be protective in the heterozygous state (GT), with an OR of 0.55 
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(CI: 0.34-0.89).  At this SNP, the case population exhibited a 1.4 fold decrease in percent 
heterozygosity compared to controls.  These two SNPs are located within Hdac9 introns.  
However, according to one shorter Hdac9 splice form (USCS Genome Browser), these two 
SNPs are located before the gene’s 5’ start site.  If upstream of Hdac9, the significant SNPs 
found could alter gene expression through some sort of regulation.  If they are found within non-
coding introns, they could affect gene and protein expression by altering mRNA splice sites.  In 
addition to these possible genetic implications, the SNPs could also affect a later functional event 
that we have not studied yet. 
 A second region of 22.3kb also maps to Hdac9 on chromosome 7.  We identified two 
important SNPs here.  The case population at rs6974011 had a genotype distribution that 
deviated from HWE at p=0.038.  Additionally, the heterozygote (CA) and homozygote (AA) 
genotype both had OR < 1, indicating that both genotypes are implicated in SCC protection.  
This also indicates that the ‘A’ allele acts in a dominant manner and plays a role in resistance, as 
its presence in either the heterozygote and homozygote genotype results in a protective state of 
SCC.  Also in this region was rs12699991.  The case population here had a genotype distribution 
that deviated from HWE at p=0.001.  This SNP is identified to be protective in the heterozygous 
state (AG) with an OR=0.57 (CI: 0.35-0.94).  Also significant was a 1.4 fold decrease in the 
cases compared to the controls (51.47% in the cases and 35.80% in the controls). 
 This region of interest we identified (rs6974011 and rs12699991) was found to affect the 
occurrence of SCC.  Having a heterozygous genotype at each of these SNPs seems to be an 
indicator of SCC outcome and a lower prevalence rate of SCC.  The identification of a number of 
SNPs that are associated with protection for SCC can provide additional information to the exact 
role of Hdac9 in this disease.  These polymorphisms in the intronic non-coding region of the 
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gene could affect mRNA splicing, gene expression, and protein production in some way that 
confers a greater resistance to the disease.  Other studies in Dr. Toland’s lab have seen an 
increase in Hdac9 protein levels in skin cancer resistant Mus Spretus, indicating a possible role 
of Hdac9 in regulating and silencing oncogenes that contribute to SCC resistance (Fleming, J.L. 
personal communication). 
 
5.2 Chromosome 11 
 Chromosome 11 did not exhibit significant differences in percent heterozygosity between 
the case and control population.  A number of individual SNPs exhibited noticeably different 
heterozygosity percentages.  No ROH was identified to be significant and unique in the case 
population when compared to controls.  The case population deviated from HWE (p<0.01) at 
8/20 SNPs (40.00%) that were genotyped for validation.  Control populations deviated from 
HWE (p<0.01) at 1/20 SNPs (5.00%) that were genotyped for validation, suggesting an increase 
in deviation from HWE in the cases compared to controls.  A number of SNPs were implicated 
in increased SCC risk or resistance, as mentioned earlier.  
 Two of the significant SNPs, rs2587550 and rs2734839, were located in or around the 
gene DRD2, the dopamine receptor D2 (13.5kb region) (Figure 9).  This gene encodes the D2 
subtype of the receptor for the neurotransmitter dopamine.  Case populations for both SNPs 
deviated from normal HWE (p<0.01).  Both were also found to be protective of SCC in the 
heterozygous state; heterozygotes at these SNPs seem to have a lower risk of SCC development.  
rs2587550 occurs upstream of DRD2, potentially affecting functional characteristics we have not 
studied, such as gene regulation by enhancers and suppressors.  In addition to being protective in 
the heterozygous state, SNP rs2734839 was significant in that it indicated an increased risk of 
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SCC in the homozygous state (GG) (OR: 2.87, CI: 1.62-5.08).  This SNP exhibited a noticeable 
change in percent heterozygosity; the case population had a 2.7 fold decrease in percent 
heterozygosity (43.56% controls and 16.13% cases). 
 Our findings of susceptibility and risk SNPs at DRD2 require further investigations and 
functional studies to determine whether or not it is a susceptibility gene to SCC.  With its 
significant OR and the large difference in homozygosity and heterozygosity frequencies between 
the cases and controls, rs2734839 seems to affect SCC risk.  Individuals with a genotype of GG 
at this SNP could be more susceptible to SCC than individuals with a heterozygous genotype of 
GA.  This suggests that the ‘G’ allele acts in a recessive manner, since two copies of the allele 
are associated with and predictive of the SCC phenotype and one copy of the allele was not.  
Thus, individuals with homozygous GG are at a higher risk of developing SCC than those with a 
heterozygous genotype.  In previous studies, other polymorphisms in DRD2 have been 
associated with colorectal cancer and non-small cell lung cancer21,22.  Its role in skin cancer is 
unknown, and additional research is needed to find its genetic influence in SCC. 
 Another region of interest that included SNPs rs752806, rs10893564, rs7127398, and 
rs1793668, was centered around the gene KIRREL3 on 11q24 (Figure 9).  KIRREL3, kin of 
IRRE like 3 encodes a protein of the nephrin-like protein family that is expressed in the fetal and 
adult brain and podycytes of the kidney.  Case populations at three SNPs (rs752806, 
rs10893564, and rs1793668) deviated from HWE (p<0.01) while the controls stayed within 
normal expected values and HWE.  SNP rs752806 is located upstream of the KIRREL3 start site.  
In addition to the genotype distributions deviating from HWE, the homozygous state (TT) of this 
SNP is associated with an increased SCC risk (OR: 1.82, CI: 1.01-3.27). Its upstream location 
indicates that it may affect gene regulation and downstream expression. 
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 The other three SNPs in this region are all located within the 166kb of the gene 
KIRREL3.  rs10893564, rs7127398, rs1793668 are all identified as protective SNPs to SCC.  
The case population exhibited a 1.8 fold decrease in heterozygosity at rs7127398 compared to 
controls (61.29% in controls and 33.33% in cases).  Also, rs1793668 shows interesting 
characteristics: it is protective for SCC in both the heterozygous (CT) and the homozygous (TT) 
state.  This suggests that the ‘T’ allele acts in a dominant fashion, resulting in a protective state 
or phenotype whenever it is present in the genotype.  The presence of the protective SNPs 
suggests that KIRREL3 is a potential candidate resistance or tumor suppressor gene that 
promotes a protective phenotype to SCC.  The distribution of the case population at these SNPs 
were p<0.01 (case population genotype distribution was non-significant with p>0.01), indicating 
that some characteristic of these SNPs is pushing the population out of normal HWE, whether it 
is a specific allele at the SNP or its functional targets.  These SNPs are located in introns, and 
could alter the mRNA transcript and splicing activity in a way that contributes to SCC resistance.  
KIRREL3 and its relationship to cancer have not been thoroughly studied, and further 
investigation of its effect on cell growth could provide more information on its exact functions. 
 
5.3 Conclusions and Future Work 
 We were not able to prove the first hypothesis of this study.  ROH for the regions 
included in this study did not appear to be more common in SCC cases than controls.  Even 
though a handful of SNPs exhibited noticeably different rates of heterozygosity and 
homozygosity between cases and controls, homozygosity overall does not seem to have a 
significant effect on SCC prevalence and susceptibility.  Therefore, homozygosity and ROH on 
chromosome 7 and 11 do not seem to play a role in SCC predisposition.  Because this was not a 
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genome wide association study, we cannot conclude that ROH is not prevalent at other loci SCC 
cancer patients.  It is possible that if thousands of SNPs across the whole genome were scanned, 
ROH important in SCC susceptibility could be identified on other chromosomes. 
Our second hypothesis was to determine SNPs associated with SCC risk and protection.  
We identified a number possible candidate genes housing SNPs associated with increased SCC 
risk and resistance.  Hdac9 on chromosome 7 contains three SNPs (rs2520458, rs6974011, 
rs12699991) associated with protection and one SNP (rs3807917) associated with increased SCC 
risk.  DRD2 on chromosome 11 appears to also be protective in heterozygous states and cause 
increased risk in homozygous states at a few SNPs (rs2587550 and rs2734839).  KIRREL3 also 
houses three SNPs associated with protection in the heterozygous state (rs10893564, rs7127398, 
rs1793668).  These three genes seem to be potential candidate SCC susceptibility or tumor 
suppressor genes.  SNPs from introns and non-coding regions have the potential to alter gene 
expression.  These areas are important in gene regulation; the consequences of SNPs include the 
alteration of splice site sequences that are used by spliceosomes, or a change in the ability of 
transcription factors to bind and regulate transcription.  
These SNPs and genes warrant additional study on their potential role in SCC.  Currently, 
there is little literature on the relationship between DRD2, KIRREL3 and skin cancer.  Functional 
studies can be done to determine the effect these genes have on SCC development.  This includes 
cell culture studies, in which proliferation, apoptosis, and protein production can be measured.  
Findings from future studies may yield insight on the importance of these two genes in SCC. 
Because the SNPs in this study were chosen from previous experiments, there is a 
possibility that other significant SNPs on chromosome 7 and 11 were not included in this study.  
Additionally, other SNPs associated with SCC could be located on chromosomes that were not 
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studied here.  By conducting two rounds of genotyping in this study, it is possible that non-
significant SNPs from the initial round of genotyping round could in reality, be significant.  A 
complete genomic study could potentially be used to identify not only other ROH, but also 
additional SNPs that may be important in SCC susceptibility. 
 
5.4 Significance 
Runs of homozygosity of normal DNA in cancer patients is a relatively newly described 
phenomenon.  Significant increases in homozygosity and ROH throughout the genome in normal 
DNA from SCC patients can indicate regions that may harbor susceptibility genes in skin cancer.  
Additionally, by studying the allele and genotype distribution across SCC patients and controls, 
each SNP can be analyzed for ORs.  SNPs with differing genotype distributions between the 
cases and controls can be linked to SCC as either protective or susceptibility SNP genotypes.  
The genes that these SNPs reside in can then be identified as candidate genes that affect cancer 
predisposition. 
Genetic studies of cancer are often conducted not only to understand the biology of the 
disease but also the development of prevention and treatment options.  In order to identify future 
novel and effective target therapies, it is important to understand SCC at a genetic and etiologic 
level.  The ability to identify tumor suppressor genes and oncogenes that are affected during 
tumor initiation and progression could facilitate the identification of novel molecular targets for 
therapeutic intervention and diagnostic biomarkers.  Identified biomarkers could be applied and 
further used to determine both the predisposition to skin cancer and to predict the outcome of 
SCC in humans.  Results from this study can help determine the genetic mechanism of the 
development and progression of SCC. 
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Figure 8: Significant SNPs on Chromosome 7. SNPs located within the introns of the gene 
HDAC9.  SNPs rs3807919 and rs2520458 are located upstream of the gene based on a second 
HDAC9 splice form.  Blue: SNPs with OR>1 indicating an increased risk of SCC.  Green: SNPs 
with OR<1 indicates protection.  Purple: SNPs with a genotype for protection and a genotype for 
increased risk of SCC. A * indicates a p<0.01 in the case population (deviation from HWE).  
 
 
 
Figure 9: Significant SNPs on Chromosome 11.  SNPs located at genes DRD2 and KIRREL3 
on chromosome 11.  Blue: SNPs with OR>1 indicating an increased risk of SCC.  Green: SNPs 
with OR<1 indicates protection.  Purple: SNPs with a genotype for protection and a genotype for 
increased risk of SCC. A * indicates a p<0.01 in the case population (deviation from HWE). 
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SUPPLEMENTAL 
Table 1: Sequenom Primers for Initial Genotyping 
SNP Primer Sequence 
CHROMOSOME 7 
Forward  CATAAATCGGATAAGGCCAT 
Reverse TACAGGGTAGAAGGCGAAAG 
 
rs12699991 
Extension CTTCTTGCAGCCTTTGG 
Forward  TGAACGTACGTTCTCTTCCC 
Reverse CCACATTGAAAAAGGGATG 
 
rs10486048 
Extension CGTTCTCTTCCCATACTC 
Forward  ATAGACTTTGCCAGAGGCCA 
Reverse CCACATGTATGAGTTTCCTG 
 
rs6968777 
Extension GCCAGAGGCCAAATATAA 
Forward  GGAGCAGAGGACCTACCAG 
Reverse TGCAGCTGCAGCTATGGAC 
 
rs2520456 
Extension caCTACCAGGTCCCCGACT 
Forward  TTGTGCTCACTGCTTAAGGG 
Reverse GGAATCAGAGTTAGAAAAGTC 
 
rs2239926 
Extension ggTAAGGGACATCCTAGGG 
Forward  AATTGGAACTAGGCTGGGCG 
Reverse TGACCTCAAGTGATCTGCCC 
 
rs801759 
Extension CAGCGGCTCATGCCTATAAT 
Forward  TCTCCAAGTTACGGATGAGG 
Reverse GACTCTTTCATGTGTGTAAC 
 
rs2520458 
Extension gggCAGAGGCCTAGGGAAAT 
Forward  GAAGCAAATAATGGCATCAG 
Reverse TTCATATCCCTTTGATGCGG 
 
rs7808451 
Extension AGTGCTATAATGCACAAGAAA 
Forward  TCATCCACTGGATACCTA 
Reverse GGGTTACTTTTATAATAAAGC 
 
rs12540224 
Extension ccaCACTGGATACCTATGTGCT 
Forward  GGTGTTGGAGGCATGAATTG 
Reverse CTGCCCCTGGAGTTTTTAAC 
 
rs2704284 
Extension ggTGGAGGCTGAATGTGAACCA 
Forward  TGTTGGAATGATTTCAGTGC 
Reverse CGATCTTTATTCTTTTGTTGC 
 
rs2526633 
Extension TGGAATGATTTCAGTGCTCTTTA 
Forward  TCAGCAATTTGCACTCTGCC 
Reverse CAATTGAAGTCACCTGTTTG 
 
rs2073973 
Extension cccATTTGCACTCTGCCATGAATC 
Forward  TAATGAAGGGTAGTTATC 
Reverse CCTCTCTTGACACATATGAA 
 
rs10486329 
Extension taagGAAGGGTAGTTATCTCCTAA 
Forward  GGCAGCAAGGTACAAAACAC 
Reverse TTCAACTGTGTGGAGTTAC 
 
rs1034805 
Extension catggACAAAACACACTTTGCTTTA 
Forward  TACCTAGCGAAGAAAGAAGG 
Reverse CTCTCTTCTGAGTGAGATTC 
 
rs10237366 
Extension ggaTAGCGAAGAAAGAAGGAACTCT 
Forward  CTGGAAAGATACTTGCAGAT 
Reverse AGCTACCCACAGTCAGTATC 
 
rs6461065 
Extension gcTGCTACAAAGATTAATCAACAGGT 
 48 
Forward  TCAGTAACTGCTGTCTCTGG 
Reverse CTAATGGAAAAAGCATAAATG 
 
rs2040623 
Extension cctTCTCTGGCCACTCAGGAATACATC 
Forward  TACAAAAGGTACATATTTTC 
Reverse GCCAGAAGAGGCATACATTG 
 
rs1554774 
Extension ttcACATATTTTCAAAAGTACTACTTG 
Forward  GCCGAGGGCTGCACCATCC 
Reverse GTACATGAATCGGAGCTCAG 
 
rs8177374 
Extension CACCATCCCCCTGCTGT 
Forward  GCTTTATAGATTTAGGTGC 
Reverse AGGATCAATAGAGCAAAAGG 
 
rs10225248 
Extension GATTTAGGTGCTCCGAT 
Forward  CCAAAGAGAGCTGTTCGATG 
Reverse ACTTTCAGTTAATGCTGAG 
 
rs11764843 
Extension TGCCCTGCTGTTTTTTAT 
Forward  GATGGTCCTGGGAATTTATC 
Reverse CACAGTTTAACAACGATAGC 
 
rs1405618 
Extension ATGACCGGGGAAAGAGTG 
Forward  GGATCTAGCACTTGGCTAAC 
Reverse TTATCTCACTCTGGGCTGAC 
 
rs17140399 
Extension acGGCTAACTGGCTGTAAT 
Forward  TGCCCCCAGCATAAGCAAAC 
Reverse TGTCATGAATCAACTGATGC 
 
rs3213615 
Extension ctCAAACAATGCACACACAT 
Forward  GGAAACTGCAAATGACTTGTG 
Reverse CTCCTGCCTACCTTTCTGAC 
 
rs3807917 
Extension AAATGACTTGTGATTGGACT 
Forward  CTGTTCTTTTCTGATAATGC 
Reverse TGCAAACAGTATTCCACAGG 
 
rs2214867 
Extension TGCAATTCTGTTTGTCTTACT 
Forward  GAAAGAAAAGATGCTGGTGG 
Reverse TCTGCACAAATGATCTTGCC 
 
rs7796078 
Extension ggAGATGCTGGTGGAAATCAT 
Forward  CTTCAAAATATCCTGAGGG 
Reverse GCTGTGAAGGTAGAGAGAAT 
 
rs11543651 
Extension gtcATATCCTGAGGGTTTTTTG 
Forward  TCCAAGTGACAACCCATAG 
Reverse CCATGGTGACATGATAGAG 
 
rs6461387 
Extension cGTGACAACCCATAGTCTAACTA 
Forward  GGCTAATTTTCAGAGAAAGTG 
Reverse CAATAAATAAGAAACATTTG 
 
rs726116 
Extension CAGAGAAAGTGGTAATTCAATGC 
Forward CCTAAAGGAAACTATTTACTC 
Reverse CTTCATCATAAAGCTAACC 
 
rs6947529 
Extension ccTACTCACATTTAACACCAAACT 
Forward  TTCTGGGAACCTCACAGATG 
Reverse AGGCATTAGGGATACTTGTG 
 
rs2853552 
Extension GGAACCTCACAGATGTTTCTATTA 
Forward  ACATTAAGTAGGGGCCTTTC 
Reverse GACATACTGTAAAGCACAAC 
 
rs3801986 
Extension gTTAAGTAGGGGCCTTTCTTTAGAG 
Forward  TCAACCCTTTTTCAGGAACG  
rs17350355 Reverse AACAGCATGGAATAAAGACC 
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 Extension cccttAACGACTTTGTCTAGTCATAT 
Forward  ACCTATAATGCTTGTCTACC 
Reverse AATACTTGTCAGCAAGTTA 
 
rs2237298 
 Extension agAATGCTTGTCTACCTCATTGTGTA 
Forward  TAGCCCTATCATACATGTGG 
Reverse CCTGAGGAATGTGCATAAGG 
 
rs6974011 
Extension ggggCTAGATTCTTAGGAATCTGATG 
Forward  AAAAATGCCAGCCGAGTGTG 
Reverse GTACACATGCCACTGAAACC 
 
rs2158768 
Extension TGGCTACCCAGGTGAAG 
Forward  TGTGGAAGACCCTTCCACTG 
Reverse GTGGTGCACGTTGAGACAG 
 
rs12700003 
Extension GCTATGTCCACCTCAGAA 
Forward  TCTGAACACCTGCATAGGAG 
Reverse GAGATAACAGACAAGTCCAC 
 
rs7811989 
Extension TAGGAGTTGACTGTAGGGA 
Forward  GAAAATGATGACCAAAACAGG 
Reverse GGGAAAATATCATCTCTCACC 
 
rs7783171 
Extension ACCAAAACAGGATTTTGCTT 
Forward  CAACTGGTGCATTTGGTATC 
Reverse CCATCTTACACCAAGTCAAG 
 
rs2695027 
Extension TTCAAAAGGTTTAGCAGATT 
Forward  CTTGATGCCAACCATTACAC 
Reverse GGGGTGTGTATATTTCAAC 
 
rs2158041 
Extension GCCAACCATTACACAATTTCC 
Forward  GGTTGAGCAATAGATATTGG 
Reverse GAAACAAATAACTACTTGTC 
 
rs212664 
Extension GCAATAGATATTGGATGAACA 
Forward  GGAAGGATGACGGTTTTGTG 
Reverse CAAGATGCTCTCACAGATGG 
 
rs6590224 
 Extension ccccGACGGTTTTGTGCCTTAT 
Forward  TCTCTTAGCTTCCCCTTATC 
Reverse GCTAATTTGCAAAATGGTTC 
 
rs17140423 
Extension CTTTAGGAATGTTTGAACATCT 
Forward  AAGGACATGAGGTGGGATTG 
Reverse GATGGGCTATCCTTTGCCTG 
 
rs2073964 
Extension tTGGGATTGGTAGAAAGAAAAT 
Forward  CAGAAAAAGACAAAGAACC 
Reverse GCAAGAACAGCCAAATGCAG 
 
rs6969316 
Extension GAAAAAGACAAAGAACCTTAGTC 
Forward  GCTTTATTCCTTTAATAGTC 
Reverse TAGCAACTGGGTGTTCAAAA 
 
rs726805 
Extension TATTCCTTTAATAGTCACTATGAA 
Forward  ACTACACAGTCCCTTACATC 
Reverse TCCAGCATGTTAAGATGGC 
 
rs2695029 
Extension CTTAAAGTATGGTGAAAAATGTAC 
Forward  ATCTGGGACTTCCAGTATC 
Reverse CTCAGGTTGCCATAGGTTAG 
 
rs2520362 
Extension ggggtTATCCAGAACTGTGAGAGA 
Forward  AGTCAGAATATCCATACTC 
Reverse ACAAGAAGGCCATCTCGTAG 
 
rs 17349342 
Extension atTCAGAATATCCATACTCAGTTGAA 
rs10247238 Forward  GCAGTTGTCATCTATGTTT 
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Reverse GCAATAACATGACTTTAGGC 
Extension gtATCTATGTTTTACAAATGAGAAAA 
Forward  TATGTGGTCGCTTCTGACTG 
Reverse AGTACTGAGTTACATGCTAC 
 
rs801763 
Extension ccctaCTTCCTTTACTCAGCATGGTTT 
CHROMOSOME 11 
Forward  GTGCAATTCCTTTTGCTGGG 
Reverse AGCATTTGTGCTGAGTACTG 
rs6589400 
Extension CCTCTCCCCACTCAG 
Forward  ACCCACGACTAGCCAGAACT 
Reverse TGACTCCAGGGTCCTCCCTT 
rs4938023 
Extension ACTGCCTTCCCCAAA 
Forward  TAGTGAAGTGTGCAATACGC 
Reverse TCTTTCCAAGAGTCAGTGCG 
rs2508557 
Extension AGGCACACGTACAGG 
Forward  AATTGCTCAGGCTCCGTGAT 
Reverse CAGGAAAGGCACAGGAGCG 
rs4245147 
Extension GCTCCGTGATGTTGTT 
Forward  TCTAAAAGGCATTCGCTCCC 
Reverse ATACAAACCCAGCTCTGTGC 
rs9971527 
Extension gaTCCCCCTTCCTCTCC 
Forward  CATTAGCGATGAAAACAGAC 
Reverse TTTTCGTCTAACTCCCTCCG 
rs1943528 
Extension gtTCCTACCTCCGCGAA 
Forward  TAATCCTTGGGTGTAGAGGC 
Reverse CACTCATTTCAGACACACAC 
rs238903 
Extension AGGCACAACTGACTTAA 
Forward  ACTCCTACCCTAGGGTAATC 
Reverse AGTCAGAGAGAGGAAGTAGC 
rs12802646 
Extension CCTAGGGTAATCCTCCAC 
Forward  AGATTTTAACGTGCAGGCTC 
Reverse TGGAAAGTCAGATGTGAGCC 
rs2587550 
Extension gatTGCAGGCTCGGTTTA 
Forward  CCATCTTCCCCAGTACTGTG 
Reverse CATATGGGTGCAATGGCCTG 
rs667627 
Extension tatgCTCCCCCTCCCCAGT 
Forward  AAAGAAGCCGTTGGTCTTCC 
Reverse TCCATTTTGGAGAGCTCTTC 
rs2106234 
Extension gatgCCCACTCATACCGCT 
Forward  TGTCATAAAGGAGGTCCTTC 
Reverse ATGCAGAATCTAACTGGGTG 
rs1997547 
Extension CCTTCAGTCTTCCTAACTTC 
Forward  GGCCATCTTGTCTTCACTTG 
Reverse CAATCTGTCTACCTCTCAGC 
rs7110377 
Extension cgttTCTTCACTTGTTCCCC 
Forward  GCAGATAGAGCAATGGGTTC 
Reverse ATCACATAACTGGCCCCTTG 
rs1946050 
Extension CTGGCTTTTGCCTGCATTAA 
Forward  CGCAACTAGATGTTTAAGGC 
Reverse ATACTCTGGTATCTGCTGTG 
rs2734839 
Extension GCCTGGTCATCTTAGATATA 
Forward  ACACTGGTGCAATGCCAAAC rs7937122 
Reverse TTGTTCCTCTGCAGGTGACT 
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Extension caCGTGCAAGGAATGATTTAG 
Forward  AGAAGTCTGAGGACTCCAAG 
Reverse ACCTGCTCAATGTCGGTGTC 
rs1713676 
Extension ggtggGGTAGCAGAAACCAGC 
Forward  TCAGGTTTCTCTGGTTAAGG 
Reverse CAGTTACTTGCCATGCTCTG 
rs638766 
Extension TTGCCTGCAACTACATCTGTTA 
Forward  CATCTCAATCTTCTTTGTGGC 
Reverse AGAAGAGGATGGAACTCTGG 
rs1509513 
Extension ccagCCTTGGCTTACAGATTGT 
Forward  GTCAAGACATTGAGCTAGAG 
Reverse TCCCACATTTAATGCGTTCC 
rs10750355 
Extension tCTAGAGAAGAGCAGATGAGAA 
Forward  TGGAGTCAGACCCTCCAGC 
Reverse TGGAGCAGCCCTTCCCTGT 
rs582037 
Extension cccttAGACCCTCCAGCAGCACC 
Forward  ACCCACCCCCTGCAAATTTA 
Reverse CTTTTAGGGTGGAATTTCTC 
rs624590 
Extension ccaaCCCCTGCAAATTTACCAGTA 
Forward  GTTATATCATGGGACCCC 
Reverse CACATTTGTGGGAATCCGAG 
rs8177376 
Extension gtgggATCATGGGACCCCGGAAAT 
Forward  GCAGGGATATACTGCAAACG 
Reverse AATGTGCCAGCACAGCTTTC 
rs10893564 
Extension cctcCTGCAAACGTAATTCAGAGTA 
Forward  AACCACGATGAGACTCTGGA 
Reverse TCAGGGAAGGAAATCCCAAG 
rs648710 
Extension gaaAGAAGCTCCCAGGGCCTTTGAA 
Forward  TGAAATTGCTCTTGCTGAGG 
Reverse GTGAAGACTGACAATAGACC 
rs11220473 
Extension tgcaAATGACCTTCTAATTGCCAAAC 
Forward  GCTGTTTAGTCCTAACTTGC 
Reverse TTGTGATCAAAACCCTAGCG 
rs4935987 
Extension tcctcACTTGCTTAGTAGAAAACGTC 
Forward  CTTGGTTCTCTCCCCTTCAT 
Reverse CAACACTTCGGGTATTTGGC 
rs238914 
Extension ttccTTCTTCCCAAAATTCCAACCAGT 
Forward  CAAGGATTATGAAACCCGAG 
Reverse AATTGTGAAGTTGACCCTGC 
rs2097078 
Extension gtagGTAGAGGGCTGACTTTTCCTATA 
Forward  TCCGGGCTGCTCACTTTAGA 
Reverse ATACAAAGGCAGGCTGGCTC 
rs7933647 
Extension ccatGGCCCGCCCCCCGCAGGGCCAAGA 
Forward  GACCACCCTTAGGTAAGACA 
Reverse CTTTGGAAAATCTTGGGTGC 
rs648181 
Extension cccaCCTTAGGTAAGACAGGGTAGATAA 
Forward  GCAGGAGTGATAGATGGTTC 
Reverse GGCCAACGTGCTCTTAATTG 
rs1106804 
 
Extension gggaGCAGCTTCCCAATTAGATGGATAC 
Forward  TTCTTCTGCTAGCCACAACC 
Reverse TGACTTGTGTGAGAATGTGC 
rs676982 
Extension GCCACAACCATCTCT 
rs7127398 Forward  AGACCATGTGATACTAGCCC 
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Reverse TTGGTTGCCATCCCATACAG 
Extension TAGCCCCAAAGGGAG 
Forward  CATGTTGGGTCCAGAACACG 
Reverse TGTGATGGAAAGAGGACAGG 
rs2459976 
Extension GCAGGAGCTAGGGTC 
Forward  TTTTGTTGCCTCCATCCAGC 
Reverse CTTGGTCTGTTATAGCTGCC 
rs12361261 
Extension CCAGCCCCAAAGGGCTA 
Forward  GATGCAAAGACTGCCTGGTG 
Reverse TCTTCCCAGATGGTTCTTGC 
rs1793668 
Extension ttcGTCATGAGGCCCTTC 
Forward  CCTTCCTACCTGTGGCTTAG 
Reverse GACTCCATCTCAGCAAGGAC 
rs17626940 
Extension CCTGTGGCTTAGTAAGAC 
Forward  TACCAAGCAGTCTAAACCCC 
Reverse ATCTGGGCCCCCGATATCAT 
rs1176746 
Extension cCCCCACAGAAATACACAC 
Forward  TCTGGATTGAATCCACCCAC 
Reverse GCAGTTGATAGCTCTGATTG 
rs752806 
Extension GGAGTCAGCCTGTAGGTTT 
Forward  GGATTTAGGGTTTACTCTCC 
Reverse CTTTTAGTCACCAAGGCAGG 
rs238935 
Extension cccaCTAGGCCTGAGCCTCG 
Forward  AAGATGAGTCCTTGCTTCCC 
Reverse AGAGTTGGGAGGCCAAGAAG 
rs17656 
Extension GCTTCCCTCAGAAATAAAAG 
Forward  CTTTTACTCAGCTGTTGTGC 
Reverse AAACATCCCGGAACTAGAGG 
rs695077 
Extension ccttTGCTGGCTTCTCACAGA 
Forward  AGGGAGAAGCTACAAGCCTG 
Reverse CTCCATAGGAGCCCTGGAT 
rs7925175 
 
Extension ATGTGGAGTATACCCAGTAGG 
Forward  CCTAACAAGAGAATGGGCTG 
Reverse GCAGCTTTTCATGGTGCTAC 
rs612592 
Extension tattAAAAGGCTTTCCCTGCGG 
Forward  ACAAACTTTCCAGGAACAGG 
Reverse TCGGTTTGTTCAAAGGCCTG 
rs7941136 
Extension CAGGAACAGGAATTCTCATAGT 
Forward  CAGGGAATGGACTTAGGAAG 
Reverse TCCCTACTTCCTGCATTTGG 
rs371267 
Extension cctcTTGGTTTATTTGCTACCCA 
Forward  TCTACATTCTTCTCACAGCC 
Reverse TCTGGCCTTTCTAACTCAC 
rs11220409 
Extension ccccCTCACAGCCAAAAAGGAAC 
Forward  TCACTGGGAGATGCCATCAA 
Reverse AGTTCCCAAACAACAGTAGG 
rs2230279 
Extension agGGGAGATGCCATCAACAAGTA 
Forward  ACCTGATTTCTCTAATCAGC 
Reverse AGGAATCTGTCAATGATGG 
rs655988 
Extension agCATGCAAAACATCATGGACATC 
Forward  ATACTCTGGTATCTGCTGTG 
Reverse CGCAACTAGATGTTTAAGGC 
rs2734839 
Extension atcttGTATCTGCTGTGCGTTTGT 
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Forward  ACACTGGTGCAATGCCAAAC 
Reverse TTGTTCCTCTGCAGGTGACT 
rs7937122 
Extension gcttCCCGTGCAAGGAATGATTTAG 
Forward  AACTATCCCCACATGAGGAC 
Reverse GGGAAAGATTACTATAGGGC 
rs7115090 
Extension ccccCATGAGGACAGTGACCAAATCT 
Forward GTCATTCTTTGTCATTGGGC 
Reverse CTTTTTGGTAGACCTGTCAA 
rs6589396 
Extension GCATTTATTATTAGTTGCAGTTAGAA 
Forward  ACAGTCATGTTGTATGAGGG 
Reverse ATATGCCCATTACCCAGGTC 
rs11214741 
Extension gagggGTATGAGGGGTCCACACTGAA 
Forward  GCTCAGTGCCCTGAGAAATA 
Reverse GTGACCAGTTGGTGTTTAAG 
rs4534613 
Extension ctccCAGTGCCCTGAGAAATATCCACAC 
Forward  CTGTGGTCCAAGGCCATTTT 
Reverse TTAAGAAGAGCTGTGTGCCC 
rs591163 
Extension cctaCAAGGCCATTTTTGCTGGCTGTAC 
Forward  CCAGGAACACACTGGAATCT 
Reverse GTGAGTGGCTTCACCAAACC 
rs240537 
Extension gattGAATCTGAGTCTAATTTCTCTGAG 
Forward  CCTGCTTTCACACCGTCAG 
Reverse CCTGTGCAGTTTTGATGCTC 
rs625496 
Extension CACCGTCAGTGGGAT 
Forward  TTCCTGCTCACGGTTCGCAA 
Reverse ATCCTCCACTGCTGACTCTG 
 
rs6276 
Extension AAGGGTGAGGCTGGC 
Forward  TAACCCCGCTTTCATACGTC 
Reverse GTTTCACGGTGTGATACTGG 
 
rs586566 
Extension GAAGAGGGTGGGCTGG 
Forward  TTCTTGGCACACGTTCAAGG 
Reverse CAGACTCTCTTAGTACAGCG 
 
rs612841 
Extension ACGTTCAAGGGCCCACA 
Forward  CAAACTCAGCTCATACAGAC 
Reverse ATCCTCAATACTGCACTCCC 
 
rs11214677 
Extension AGACTCTGGGATAGGAA 
Forward  GTATGGCAGTTGAAGGACAC 
Reverse TGAGCGAGTAGGCAATGAAC 
 
rs1628588 
Extension ttGACACACGACTTGAGG 
Forward  GGTCTAATGAGACAAAAGGC 
Reverse TTCTATGGCTGTCTTAAGAG 
 
rs4471464 
Extension GGTCTGCTTGGAAAGAGA 
Forward  ACCTGAATTTGGTCACCTTC 
Reverse ATGCTTGGCCATCACCAAAC 
 
rs499205 
Extension ggACCTTCATCCTGTTGTCC 
Forward  CCTAGAAAATCTTGCTTGTG 
Reverse GGTGTTCCTAGGTTTTTGC 
 
rs1786704 
Extension gaAAAAAAGTTCAGAGGCTC 
Forward CCCTGGCATTGTCTTCATCA 
Reverse ATCCCTTCAACCTCTCACCT 
rs763857 
Extension aAAGAATGGGGTTAGGGATC 
Forward  GAAAGCCTGCATGTTTATTG  
rs10893604 Reverse GCAGAAGGAAAGGGAATTGG 
 54 
Extension TGTTTATTGATAACAACCTGA 
Forward  GTCTACATACATGTAATGG 
Reverse CCTTCAGAAATAAAGATGAG 
 
rs11214716 
Extension GATTATTATTGTTGAAGTGAGAC 
Forward  CAGATGACATTTCTTTGTTAG 
Reverse CCCACCTCCTGCTAACATTT 
 
rs11220621 
Extension TTCTTTGTTAGAAGTATAGGATTTT 
 
 
 
Table 2: Sequenom Primers for Validation Genotyping 
SNP Primer Sequence 
Forward  CATAAATCGGATAAGGCCAT 
Reverse TACAGGGTAGAAGGCGAAAG 
rs12699991 
Extension CTTCTTGCAGCCTTTGG 
Forward  AAGAGTCAGTGCGAGTGTGG 
Reverse ACAAGGCTAGTGAAGTGTGC 
rs2508557 
Extension GAGTGTGGAGTGCAGAC 
Forward  CTAACTCACAGTGATAGGAAC 
Reverse GCATGGAAGGCAAAAAATAG 
rs11220409 
Extension TGATAGGAACTTGCGCCA 
Forward  TGCCCCCAGCATAAGCAAAC 
Reverse TGTCATGAATCAACTGATGC 
rs3213615 
Extension cCAAACAATGCACACACAT 
Forward  AATTGGAACTAGGCTGGGCG 
Reverse TGACCTCAAGTGATCTGCCC 
rs801759 
Extension CAGCGGCTCATGCCTATAAT 
Forward  GGAAGGATGACGGTTTTGTG 
Reverse CAAGATGCTCTCACAGATGG 
rs6590224 
Extension ggTGACGGTTTTGTGCCTTAT 
Forward  TCCAGCATGTTAAGATGGC 
Reverse ACTACACAGTCCCTTACATC 
rs2695029 
Extension GGCAAAGAGAAATGAGTAAAA 
Forward  TAACCCCGCTTTCATACGTC 
Reverse GTTTCACGGTGTGATACTGG 
rs586566 
Extension gggGTGAAGAGGGTGGGCTGG 
Forward  CCAGGAACACACTGGAATCT 
Reverse GTGAGTGGCTTCACCAAACC 
rs240537 
Extension AATCTGAGTCTAATTTCTCTGAG 
Forward  AGAAGAGGATGGAACTCTGG 
Reverse CATCTCAATCTTCTTTGTGGC 
rs1509513 
Extension gagGGAACTCTGGAGAGCAATAA 
Forward  CTTGATGCCAACCATTACAC 
Reverse GGGGTGTGTATATTTCAAC 
rs2158041 
Extension gGATGCCAACCATTACACAATTTCC 
Forward  ATCTGGGCCCCCGATATCAT 
Reverse TACCAAGCAGTCTAAACCCC 
rs1176746 
Extension gTCATCAATGAGTTGTAAGTGTGCC 
Forward  GACTCTTTCATGTGTGTAAC 
Reverse TCTCCAAGTTACGGATGAGG 
rs2520458 
Extension agtTGTGTAACATTGAAGATGTTATT 
Forward  CCACAGGGGAGAGGAGTCA rs752806 
Reverse GCAGTTGATAGCTCTGATTG 
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Extension gtGGAGAGGAGTCAGCCTGTAGGTTT 
Forward  TTCTTCTGCTAGCCACAACC 
Reverse TGACTTGTGTGAGAATGTGC 
rs676982 
Extension TAGCCACAACCATCTCT 
Forward  TTTTGTTGCCTCCATCCAGC 
Reverse CTTGGTCTGTTATAGCTGCC 
rs12361261 
Extension CCAGCCCCAAAGGGCTA 
Forward  CTCCTGCCTACCTTTCTGAC 
Reverse GGAAACTGCAAATGACTTGTG 
rs3807917 
Extension cTTCCACCTGTGCCTTGTA 
Forward  TCACAGGGACTCAGAGTCAT 
Reverse TTCTGGCACCCATGTCTACC 
rs1793668 
Extension CAGAGTCATGAGGCCCTTC 
Forward  ATTTTAAAAGCCCCTTGCCC 
Reverse AGCTGGAGTGTGTCCTAGAG 
rs2587550 
Extension TAACGTGCAGGCTCGGTTTA 
Forward  ACCTATAATGCTTGTCTACC 
Reverse AATACTTGTCAGCAAGTTA 
rs2237298 
Extension cCTTGTCTACCTCATTGTGTA 
Forward  AATGTGCCAGCACAGCTTTC 
Reverse CAGGGATATACTGCAAACG 
rs10893564 
Extension ggggTTTGCTTTGAGCAGTGT 
Forward  ATGTTTAAGGCTGCCTGGTC 
Reverse GCTCACAACCGTGTTTTTAA 
rs2734839 
Extension CTGCCTGGTCATCTTAGATATA 
Forward  ACCCACCCCCTGCAAATTTA 
Reverse GTAATAATTCTTTTAGGGTGG 
rs624590 
Extension ccCCCCCTGCAAATTTACCAGTA  
Forward  CTGTGGTCCAAGGCCATTTT 
Reverse TTAAGAAGAGCTGTGTGCCC 
rs591163 
Extension ccccGCCATTTTTGCTGGCTGTAC 
Forward  TAGCCCTATCATACATGTG 
Reverse CCTGAGGAATGTGCATAAGG 
rs6974011 
Extension TTCTAGATTCTTAGGAATCTGATG 
Forward  TCAGGTTTCTCTGGTTAAGG 
Reverse CAGTTACTTGCCATGCTCTG 
rs638766 
Extension gcttgGCCTGCAACTACATCTGTTA  
Forward  TCGGTTTGTTCAAAGGCCTG 
Reverse ACAAACTTTCCAGGAACAGG 
rs7941136 
Extension gggaATACTTAAAGACATGTGGAAT 
Forward  ACCTGCTCAATGTCGGTGTC 
Reverse AGAAGTCTGAGGACTCCAAG 
rs1713676 
Extension gctaAATGTCGGTGTCCAGGACCGCA 
Forward  TATGTGGTCGCTTCTGACTG 
Reverse AGTACTGAGTTACATGCTAC 
rs801763 
Extension cctgaCTTCCTTTACTCAGCATGGTTT 
Forward  AGACCATGTGATACTAGCCC 
Reverse TTGGTTGCCATCCCATACAG 
rs7127398 
Extension ACTAGCCCCAAAGGGAG 
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Table 3: Primers used to sequence Sequenom-designed primers 
SNP of Sequenom 
Primers 
 Primer Sequence Tm (°C) 
Forward ACA AAG CCA CAG GAA GAA CCC AAG 59.7 rs752806 
 Reverse TTC TGG ACC CTT CCT CTC AGC AAT 59.9 
Forward TGT TCA CTG TCT TGG GCT CTG GAT 60.2 rs638766 
 Reverse ACG AGT CTG TAG TAG CAC AAG CCT 59.5 
Forward GCA GTA GAA ATG CGG TTG GAC AGT 59.6 rs1713676 
 Reverse ACA CAG GTT CTG GAG GAG GTC AAT 59.8 
Forward AAG GAA GGG CAC AGA GAG AAA CCA 60.5 rs2587550 
 Reverse ATG GAG GAC ACA AAG CTG CTA GCT 60.4 
Forward ATG GAA AGA CTT GGG AGCA GTC CA 60.3 rs2734839 
 Reverse AGA ACG AGT GCA TCA TTG CCA ACC 60.1 
Forward AGG CTG GGA TCA AGT CCA AGA TCA 59.9 rs12699991 
 Reverse TCG CTG CTT AAA GGC CCT ACC ATT 60.7 
Forward AGA GTG GAG CCA TCT GCT CAT CTT 59.9 rs10893564 
 Reverse TTG TGG GTA AGC TGA CTT GGG ACA 60.2 
Forward GGT TGT GCA ACC ATC ACC ACA ATC 59.0 rs801763 
 Reverse TTG CTG GCT CGT AAG TAC TTG CCA 60.6 
Forward GCT GTC AGC CCA ATG TCT ATC ATG TG 57.3 rs7941136 
 Reverse ATC TGT CTG GGC TCT TCC TTT CCA 60.4 
Forward TGT CCA GTG CTT CCC TGC ATA ACT 60.4 rs6974011 
 Reverse CAA CAA ATC CTG GAA AGA GGT GAG 55.9 
Forward TGC CCA CCA CAC ATC ATT GGA TCA 61.0 rs3213615 
 Reverse CTT CTC CAT TAG ATA GGG CCT CTG 56.2 
Forward ATA TGT TTG AGG GCA GGA CGA CCA 60.2 rs12361261 
 Reverse AAC AGC ACT GAG CAG GAC TCT GAA 60.2 
Forward CTG TTA AGG GCT GTG CTA CAT GCT 59.3 rs2520458 
Reverse TTT GAA GAG CCT GGT GCT GTG ACT 60.7 
Forward AGT GGG AAA GAA GCA AGG CTT GTG 59.9 rs624590 
 Reverse GGG ATG GGA GAG GCT GTT 56.9 
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Table 4: Initial Chr. 7 Allele and Genotype Frequencies 
Cases - Alleles Controls – 
Alleles 
Cases - Genotypes Controls - Genotypes SNP 
p q p q pp pq qq pp pq qq 
rs10225248 0.625 0.375 0.556 0.444 0.417 0.417 0.167 0.305 0.503 0.192 
rs2214867 0.563 0.438 0.454 0.546 0.375 0.375 0.250 0.223 0.462 0.315 
rs6461065 0.799 0.201 0.785 0.215 0.644 0.310 0.046 0.601 0.367 0.032 
rs10486048 0.124 0.876 0.110 0.890 0.012 0.224 0.765 0.013 0.194 0.794 
rs2237298 0.357 0.643 0.241 0.759 0.095 0.524 0.381 0.103 0.276 0.621 
rs2158041 0.326 0.674 0.160 0.840 0.070 0.512 0.419 0.034 0.252 0.714 
rs7811989 0.321 0.679 0.227 0.773 0.048 0.548 0.408 0.073 0.307 0.620 
rs2040623 0.818 0.182 0.753 0.247 0.694 0.247 0.059 0.600 0.306 0.094 
rs801759 0.101 0.899 0.048 0.952 0.000 0.203 0.797 0.000 0.096 0.904 
rs11543651 0.222 0.778 0.268 0.732 0.111 0.222 0.667 0.114 0.309 0.577 
rs801763 0.875 0.125 0.826 0.174 0.750 0.250 0.000 0.686 0.279 0.035 
rs2520456 0.241 0.759 0.292 0.708 0.069 0.345 0.586 0.071 0.442 0.487 
rs3807917 0.523 0.477 0.642 0.358 0.409 0.227 0.364 0.383 0.518 0.099 
rs2520458 0.682 0.318 0.657 0.343 0.506 0.353 0.141 0.396 0.522 0.082 
rs2073973 0.482 0.518 0.443 0.557 0.259 0.447 0.294 0.195 0.497 0.308 
rs2695029 0.372 0.628 0.486 0.514 0.077 0.590 0.333 0.243 0.486 0.270 
rs2695027 0.705 0.295 0.599 0.401 0.513 0.385 0.103 0.370 0.459 0.171 
rs3213615 0.538 0.462 0.693 0.307 0.346 0.385 0.269 0.477 0.431 0.092 
rs2239926 0.259 0.741 0.256 0.744 0.057 0.402 0.540 0.057 0.399 0.544 
rs2704284 0.547 0.453 0.497 0.503 0.279 0.535 0.186 0.219 0.555 0.226 
rs1405618 0.250 0.750 0.299 0.701 0.083 0.333 0.583 0.078 0.442 0.481 
rs1554774 0.707 0.293 0.739 0.261 0.500 0.415 0.085 0.562 0.353 0.085 
rs3801986 0.476 0.524 0.448 0.552 0.190 0.571 0.238 0.185 0.526 0.289 
rs7796078 0.727 0.273 0.681 0.319 0.591 0.273 0.136 0.484 0.394 0.123 
rs212664 0.268 0.732 0.341 0.659 0.122 0.293 0.585 0.145 0.393 0.462 
rs17349342 0.452 0.548 0.388 0.612 0.214 0.476 0.310 0.133 0.510 0.357 
rs7783171 0.802 0.198 0.805 0.195 0.651 0.302 0.047 0.638 0.336 0.027 
rs12540224 0.465 0.535 0.433 0.567 0.200 0.529 0.271 0.179 0.506 0.314 
rs6974011 0.533 0.467 0.316 0.684 0.333 0.400 0.267 0.096 0.440 0.464 
rs12699991 0.606 0.294 0.599 0.401 0.435 0.341 0.224 0.353 0.494 0.154 
rs2520362 0.488 0.512 0.517 0.483 0.233 0.512 0.256 0.227 0.580 0.193 
rs2073964 0.369 0.631 0.379 0.621 0.143 0.452 0.405 0.144 0.471 0.386 
rs6461387 0.375 0.625 0.43 0.57 0.200 0.350 0.450 0.158 0.544 0.298 
rs12700003 0.581 0.419 0.559 0.441 0.326 0.512 0.163 0.314 0.490 0.196 
rs10237366 0.376 0.624 0.413 0.587 0.129 0.494 0.376 0.155 0.516 0.329 
rs17350355 0.368 0.632 0.403 0.597 0.211 0.316 0.474 0.161 0.484 0.355 
rs11764843 0.619 0.381 0.581 0.419 0.476 0.286 0.238 0.356 0.452 0.193 
rs10247238 0.325 0.675 0.334 0.666 0.050 0.550 0.400 0.101 0.466 0.432 
rs726116 0.679 0.321 0.696 0.304 0.500 0.357 0.143 0.494 0.405 0.101 
rs6969316 0.345 0.655 0.268 0.732 0.119 0.452 0.429 0.085 0.366 0.549 
rs6947529 0.618 0.382 0.601 0.399 0.412 0.412 0.176 0.347 0.508 0.145 
rs726805 0.65 0.35 0.569 0.431 0.425 0.450 0.125 0.340 0.458 0.201 
rs2158768 0.439 0.561 0.453 0.547 0.244 0.390 0.366 0.220 0.467 0.313 
rs1034805 0.682 0.318 0.662 0.338 0.471 0.424 0.106 0.427 0.471 0.102 
rs2853552 0.69 0.31 0.735 0.265 0.476 0.429 0.095 0.565 0.340 0.095 
rs10486329 0.488 0.512 0.447 0.553 0.222 0.531 0.247 0.211 0.474 0.316 
rs17140399 0.354 0.646 0.384 0.616 0.083 0.542 0.375 0.152 0.464 0.384 
rs7808451 0.606 0.394 0.552 0.448 0.388 0.435 0.176 0.316 0.471 0.213 
rs17140423 0.671 0.329 0.706 0.294 0.512 0.317 0.171 0.520 0.372 0.108 
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rs6968777 0.394 0.606 0.4 0.6 0.176 0.435 0.388 0.173 0.453 0.373 
rs2526633 0.286 0.714 0.298 0.702 0.071 0.429 0.500 0.122 0.353 0.526 
rs8177374 0.833 0.167 0.832 0.168 0.708 0.250 0.042 0.698 0.268 0.034 
rs6590224 0.293 0.707 0.173 0.827 0.098 0.390 0.512 0.065 0.216 0.719 
 
 
 
Table 5: Initial Chr. 11 Allele and Genotype Frequencies 
Cases - Alleles Controls – 
Alleles 
Cases - Genotypes Controls - Genotypes SNP 
p q p q pp pq qq pp pq qq 
rs4938023 0.370 0.630 0.344 0.656 0.145 0.449 0.406 0.125 0.438 0.438 
rs11214677 0.480 0.520 0.406 0.594 0.224 0.513 0.263 0.156 0.500 0.344 
rs2587550 0.265 0.735 0.328 0.672 0.143 0.245 0.612 0.125 0.406 0.469 
rs6276 0.743 0.257 0.625 0.375 0.579 0.329 0.092 0.406 0.438 0.156 
rs2734839 0.286 0.714 0.636 0.364 0.286 0.000 0.714 0.364 0.545 0.091 
rs4245147 0.517 0.483 0.450 0.550 0.283 0.467 0.250 0.200 0.500 0.300 
rs4534613 0.395 0.605 0.419 0.581 0.186 0.419 0.395 0.194 0.452 0.355 
rs12361261 0.917 0.083 0.833 0.167 0.905 0.024 0.071 0.667 0.333 0.000 
rs7115090 0.566 0.434 0.466 0.534 0.344 0.443 0.213 0.379 0.172 0.448 
rs4471464 0.448 0.552 0.484 0.516 0.194 0.507 0.299 0.194 0.581 0.226 
rs1509513 0.567 0.433 0.556 0.444 0.467 0.200 0.333 0.296 0.519 0.185 
rs12802646 0.348 0.652 0.348 0.652 0.152 0.394 0.455 0.121 0.455 0.424 
rs7933647 0.688 0.313 0.500 0.500 0.500 0.375 0.125 0.000 1.000 0.000 
rs11214716 0.850 0.150 0.859 0.141 0.767 0.167 0.067 0.719 0.281 0.000 
rs2459976 0.563 0.438 0.652 0.348 0.292 0.542 0.166 0.485 0.333 0.182 
rs6589396 0.677 0.323 0.883 0.117 0.484 0.387 0.129 0.767 0.233 0.000 
rs1713676 0.480 0.520 0.310 0.690 0.280 0.400 0.320 0.000 0.621 0.379 
rs7111825 0.677 0.323 0.667 0.333 0.507 0.338 0.154 0.467 0.400 0.133 
rs11214741 0.453 0.547 0.362 0.638 0.209 0.488 0.302 0.138 0.448 0.414 
rs2097078 0.275 0.725 0.150 0.850 0.101 0.348 0.551 0.033 0.233 0.733 
rs6589400 0.223 0.777 0.188 0.813 0.089 0.268 0.643 0.000 0.375 0.625 
rs1176746 0.730 0.270 0.547 0.453 0.514 0.432 0.054 0.281 0.531 0.188 
rs17626940 0.145 0.855 0.214 0.786 0.048 0.194 0.758 0.071 0.286 0.643 
rs238935 0.212 0.788 0.219 0.781 0.045 0.333 0.621 0.063 0.313 0.625 
rs238914 0.271 0.729 0.355 0.645 0.063 0.417 0.521 0.129 0.452 0.419 
rs238903 0.618 0.382 0.697 0.303 0.361 0.514 0.125 0.455 0.485 0.061 
rs763857 0.353 0.647 0.359 0.641 0.133 0.440 0.427 0.094 0.531 0.375 
rs1997547 0.125 0.875 0.318 0.682 0.063 0.125 0.813 0.091 0.455 0.455 
rs2106234 0.721 0.279 0.594 0.406 0.557 0.328 0.115 0.344 0.500 0.156 
rs648181 0.708 0.292 0.632 0.368 0.583 0.250 0.167 0.474 0.316 0.211 
rs655988 0.256 0.744 0.194 0.806 0.103 0.308 0.590 0.032 0.323 0.645 
rs371267 0.700 0.300 0.717 0.283 0.550 0.300 0.150 0.600 0.233 0.167 
rs612592 0.772 0.228 0.875 0.125 0.603 0.338 0.059 0.750 0.250 0.000 
rs676982 0.732 0.268 0.576 0.424 0.536 0.391 0.072 0.364 0.424 0.212 
rs624590 0.167 0.833 0.422 0.578 0.061 0.212 0.723 0.219 0.406 0.375 
rs695077 0.230 0.770 0.100 0.900 0.060 0.340 0.600 0.000 0.200 0.800 
rs11220409 0.550 0.450 0.367 0.633 0.400 0.300 0.300 0.200 0.330 0.467 
rs17656 0.783 0.217 0.925 0.075 0.633 0.300 0.067 0.850 0.150 0.000 
rs499205 0.791 0.209 0.773 0.227 0.622 0.338 0.041 0.606 0.333 0.061 
rs638766 0.805 0.195 0.578 0.422 0.661 0.288 0.051 0.375 0.406 0.219 
rs667627 0.754 0.246 0.790 0.210 0.667 0.175 0.158 0.774 0.032 0.194 
rs591163 0.307 0.693 0.500 0.500 0.040 0.533 0.427 0.286 0.429 0.286 
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rs8177376 0.809 0.191 0.879 0.121 0.640 0.337 0.022 0.788 0.182 0.030 
rs1786704 0.195 0.805 0.258 0.742 0.035 0.319 0.646 0.091 0.333 0.576 
rs648710 0.313 0.688 0.442 0.558 0.300 0.025 0.675 0.423 0.038 0.538 
rs586566 0.760 0.240 0.864 0.136 0.584 0.351 0.065 0.788 0.152 0.061 
rs240537 0.744 0.256 0.855 0.145 0.526 0.436 0.038 0.742 0.226 0.032 
rs7937122 0.566 0.434 0.606 0.394 0.302 0.528 0.170 0.364 0.485 0.151 
rs11220473 0.557 0.443 0.552 0.448 0.314 0.486 0.200 0.241 0.621 0.138 
rs582037 0.332 0.668 0.394 0.606 0.109 0.446 0.446 0.212 0.364 0.424 
rs2230279 0.731 0.269 0.766 0.234 0.500 0.463 0.037 0.531 0.469 0.000 
rs752806 0.392 0.608 0.597 0.403 0.353 0.078 0.569 0.323 0.548 0.129 
rs7925175 0.648 0.352 0.650 0.350 0.444 0.407 0.148 0.433 0.433 0.133 
rs1943528 0.333 0.667 0.297 0.703 0.140 0.386 0.474 0.156 0.281 0.563 
rs9971527 0.786 0.214 0.636 0.364 0.629 0.314 0.057 0.424 0.424 0.152 
rs612841 0.434 0.566 0.375 0.625 0.224 0.421 0.355 0.094 0.563 0.344 
rs625496 0.591 0.409 0.578 0.422 0.364 0.455 0.182 0.313 0.531 0.156 
rs6590224 0.293 0.707 0.173 0.827 0.098 0.390 0.512 0.065 0.216 0.719 
rs4935987 0.375 0.625 0.443 0.557 0.150 0.450 0.400 0.171 0.543 0.286 
rs10893564 0.913 0.087 0.859 0.141 0.865 0.096 0.038 0.750 0.219 0.031 
rs7127398 0.707 0.293 0.629 0.371 0.537 0.341 0.122 0.323 0.613 0.065 
rs1946050 0.667 0.333 0.667 0.333 0.545 0.242 0.212 0.500 0.333 0.167 
rs11220621 0.388 0.612 0.333 0.667 0.190 0.397 0.414 0.091 0.485 0.424 
rs1106804 0.650 0.350 0.726 0.274 0.467 0.367 0.167 0.484 0.484 0.032 
rs7110377 0.462 0.538 0.150 0.850 0.462 0.000 0.538 0.000 0.300 0.700 
rs10750355 0.394 0.606 0.333 0.667 0.242 0.303 0.455 0.091 0.485 0.424 
rs10893604 0.375 0.625 0.453 0.547 0.167 0.417 0.417 0.188 0.531 0.281 
rs1628588 0.451 0.549 0.409 0.591 0.225 0.451 0.324 0.152 0.515 0.333 
rs1793668 0.363 0.637 0.172 0.683 0.290 0.145 0.565 0.069 0.207 0.724 
rs2508557 0.585 0.415 0.438 0.563 0.377 0.415 0.208 0.281 0.313 0.406 
rs7941136 0.833 0.167 0.656 0.344 0.686 0.294 0.020 0.406 0.500 0.094 
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Table 6: Chr. 7 Allele and Genotype Frequencies of Validated SNPs 
Cases - Alleles Controls – 
Alleles 
Cases - Genotypes Controls - Genotypes SNP 
p q p q pp pq qq pp pq qq 
rs2237298 0.267 0.733 0.295 0.705 0.107 0.320 0.573 0.118 0.354 0.528 
rs2158041 0.262 0.738 0.163 0.837 0.064 0.397 0.539 0.030 0.267 0.704 
rs801759 0.130 0.870 0.045 0.955 0.021 0.218 0.761 0.000 0.091 0.909 
rs801763 0.841 0.159 0.866 0.134 0.713 0.256 0.031 0.752 0.228 0.020 
rs3807917 0.504 0.496 0.594 0.406 0.287 0.435 0.278 0.326 0.536 0.138 
rs2520458 0.659 0.341 0.642 0.358 0.472 0.375 0.153 0.372 0.540 0.088 
rs2695029 0.388 0.612 0.469 0.531 0.172 0.433 0.396 0.221 0.496 0.282 
rs3213615 0.685 0.315 0.703 0.297 0.501 0.353 0.138 0.479 0.455 0.066 
rs6974011 0.417 0.583 0.307 0.693 0.231 0.372 0.397 0.102 0.409 0.488 
rs12699991 0.599 0.401 0.603 0.397 0.420 0.358 0.222 0.346 0.515 0.140 
 
 
 
Table 7: Chr. 11 Allele and Genotype Frequencies of Validated SNPs 
Cases - Alleles Controls – 
Alleles 
Cases - Genotypes Controls - Genotypes SNP 
p q p q pp pq qq pp pq qq 
rs2587550 0.293 0.707 0.298 0.702 0.140 0.306 0.554 0.078 0.440 0.482 
rs2734839 0.474 0.526 0.623 0.377 0.394 0.161 0.445 0.405 0.436 0.160 
rs12361261 0.895 0.105 0.878 0.122 0.887 0.016 0.097 0.866 0.025 0.109 
rs1509513 0.654 0.346 0.571 0.429 0.453 0.402 0.145 0.310 0.524 0.167 
rs1713676 0.493 0.507 0.485 0.515 0.289 0.409 0.302 0.226 0.518 0.256 
rs1176746 0.712 0.288 0.610 0.390 0.508 0.409 0.083 0.387 0.448 0.166 
rs676982 0.735 0.265 0.726 0.274 0.566 0.337 0.096 0.560 0.333 0.107 
rs624590 0.236 0.764 0.273 0.727 0.100 0.271 0.629 0.103 0.339 0.558 
rs11220409 0.364 0.636 0.245 0.755 0.145 0.436 0.418 0.051 0.387 0.562 
rs638766 0.763 0.238 0.723 0.277 0.619 0.288 0.094 0.554 0.339 0.107 
rs591163 0.340 0.660 0.294 0.706 0.132 0.417 0.451 0.127 0.335 0.538 
rs586566 0.749 0.251 0.780 0.220 0.582 0.333 0.085 0.617 0.326 0.057 
rs240537 0.721 0.279 0.760 0.240 0.517 0.408 0.075 0.580 0.361 0.059 
rs752806 0.461 0.539 0.544 0.456 0.270 0.382 0.349 0.302 0.483 0.215 
rs6590224 0.243 0.757 0.159 0.841 0.071 0.343 0.586 0.03 0.26 0.711 
rs10893564 0.866 0.134 0.834 0.166 0.791 0.149 0.060 0.692 0.284 0.024 
rs7127398 0.705 0.295 0.629 0.371 0.538 0.333 0.128 0.323 0.613 0.065 
rs1793668 0.366 0.634 0.285 0.715 0.189 0.354 0.457 0.085 0.400 0.515 
rs2508557 0.593 0.407 0.520 0.480 0.360 0.467 0.173 0.295 0.451 0.254 
rs7941136 0.813 0.187 0.671 0.329 0.655 0.317 0.029 0.616 0.321 0.063 
 
